<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2108234012
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BINOCRIT 30000 I.U/0.75 ml Solution For Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EPOETIN ALFA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        783.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="IDT Biologika GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            IDT Biologika GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B03XA01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Binocrit contains the active substance epoetin alfa, a protein that stimulates the bone marrow to produce more red blood cells which carry haemoglobin (a substance that transports oxygen). Epoetin alfa is a copy of the human protein erythropoietin (ee-rith-roe-po-eh-tin) and acts in the same way.</p><p>&nbsp;</p><p>Binocrit is used to treat symptomatic anaemia caused by kidney disease:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in children on haemodialysis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in adults on haemodialysis or peritoneal dialysis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in severely anaemic adults not yet undergoing dialysis</p><p>&nbsp;</p><p>If you have kidney disease, you may be short of red blood cells if your kidney does not produce enough erythropoietin (necessary for red cell production). Binocrit is prescribed to stimulate your bone marrow to produce more red blood cells.</p><p>&nbsp;</p><p><strong>Binocrit is used to treat anaemia in adults receiving chemotherapy for solid tumours</strong>, malignant lymphoma or multiple myeloma (bone marrow cancer) who may have a need for a blood transfusion. Binocrit can reduce the need for a blood transfusion in these patients.</p><p>&nbsp;</p><p><strong>Binocrit is used in moderately anaemic adults who donate some of their blood before surgery</strong>, so that it can be given back to them during or after the operation. Because Binocrit stimulates the production of red blood cells, doctors can take more blood from these people.</p><p>&nbsp;</p><p><strong>Binocrit is used in moderately anaemic adults about to have major orthopaedic surgery </strong>(for example hip or knee replacement operations), to reduce the potential need for blood transfusions.</p><p>&nbsp;</p><p><strong>Binocrit is used to treat anaemia in adults with a bone marrow disorder that causes a severe disruption in the creation of blood cells (myelodysplastic syndromes). </strong>Binocrit can reduce the need for a blood transfusion.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Binocrit:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are allergic </strong>to epoetin alfa or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have been diagnosed with Pure Red Cell Aplasia </strong>(the bone marrow cannot produce enough red blood cells) after previous treatment with any product that stimulates red blood cell production (including Binocrit). See section 4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have high blood pressure </strong>not properly controlled with medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; to stimulate the production of your red blood cells (so that doctors can take more blood from you)</p><p><strong>if you cannot have transfusions with your own blood </strong>during or after surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are due to have major elective orthopaedic surgery </strong>(such as hip or knee surgery), and you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severe heart disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severe disorders of the veins and arteries</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have recently had a heart attack or stroke</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; can&rsquo;t take medicines to thin the blood</p><p>Binocrit may not be suitable for you. Please discuss with your doctor. While on Binocrit, some people need medicines to reduce the risk of blood clots. <strong>If you can&rsquo;t take medicines that prevent blood clotting, you must not have Binocrit.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions:</strong></p><p>Talk to your doctor, pharmacist or nurse before using Binocrit.</p><p>&nbsp;</p><p><strong>Binocrit and other products that stimulate red cell production may increase the risk of developing blood clots in all patients. This risk may be higher if you have other risk factors </strong>for developing blood clots <em>(for example, if you have had a blood clot in the past or are overweight, have diabetes, have heart disease or you are off your feet for a long time because of surgery or illness).</em></p><p>Please tell your doctor about any of these things. Your doctor will help you to decide if Binocrit is suitable for you.</p><p>&nbsp;</p><p><strong>It is important to tell your doctor </strong>if any of the following apply to you<strong>. </strong>You may still be able to use Binocrit, but discuss it with your doctor first.</p><p>&nbsp;</p><p><strong>If you know you suffer</strong>, or have suffered, from:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong> high blood pressure;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>epileptic seizures or fits</strong>;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>liver disease;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>anaemia from other causes;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>porphyria (a rare blood disorder).</strong></p><p><strong>If you are a cancer patient </strong>be aware that products that stimulate red blood cell production (like Binocrit) may act as a growth factor and therefore in theory may affect the progression of your cancer.</p><p>&nbsp;</p><p><strong>Depending on your individual situation a blood transfusion may be preferable. Please discuss this with your doctor.</strong></p><p><strong>If you are a patient with hepatitis C and you receive interferon and ribavirin</strong>, you should discuss this with your doctor because a combination of epoetin alfa with interferon and ribavirin has led to a loss of effect and development of a condition called pure red cell aplasia (PRCA), a severe form of anaemia, in rare cases. Binocrit is not approved in the management of anaemia associated with hepatitis C.</p><p>&nbsp;</p><p><strong>If you are a patient with chronic renal failure</strong>, and particularly if you do not respond properly to Binocrit, your doctor will check your dose of Binocrit because repeatedly increasing your dose of Binocrit if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death.</p><p>&nbsp;</p><p><strong>If you are a cancer patient, </strong>be aware that use of Binocrit may be associated with shorter survival and a higher death rate in head and neck, and metastatic breast cancer patients who are receiving chemotherapy.</p><p>&nbsp;</p><p><strong>Take special care with other products that stimulate red blood cell production:</strong></p><p>Binocrit is one of a group of products that stimulate the production of red blood cells like the human protein erythropoietin does. Your healthcare professional will always record the exact product you are using. If you are given a product in this group other than Binocrit during your treatment, speak to your doctor or pharmacist before using it.</p><p>&nbsp;</p><p><strong>Take special care with Binocrit:</strong></p><p><strong>Serious skin reactions </strong>including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with epoetin treatment.</p><p>&nbsp;</p><p>SJS/TEN can appear initially as reddish target-like spots or circular patches often with central blisters on the trunk. Also, ulcers of mouth, throat, nose, genitals and eyes (red and swollen eyes) can occur. These serious skin rashes are often preceded by fever and/or flu-like symptoms. The rashes may progress to widespread peeling of the skin and life-threatening complications.</p><p>&nbsp;</p><p>If you develop a serious rash or another of these skin symptoms, stop taking Binocrit and contact your doctor or seek medical attention immediately.</p><p>&nbsp;</p><p><strong>Other medicines and Binocrit</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>If you are taking a medicine called cyclosporin </strong>(used e.g. after kidney transplants), your doctor may order blood tests to check the level of cyclosporin while you are taking Binocrit.</p><p>&nbsp;</p><p><strong>Iron supplements and other blood stimulants </strong>may increase the effectiveness of Binocrit. Your doctor will decide if it is right for you to take them.</p><p>&nbsp;</p><p><strong>If you visit a hospital, clinic or family doctor</strong>, tell them you are having Binocrit treatment. It may affect other treatments or test results.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>It is important to tell your doctor </strong>if any of the following apply to you. You may still be able to use Binocrit, but discuss it with your doctor first:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are pregnant</strong>, or think you may be pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding.</p><p><strong>Binocrit contains sodium</strong></p><p>Binocrit contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &ldquo;sodium free&rdquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always use this medicine exactly as your doctor has told you. </strong>Check with your doctor if you are not sure.</p><p><strong>Your doctor has carried out blood tests </strong>and decided you need Binocrit. Binocrit may be given by injection:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Either </strong>into a vein or a tube that goes into a vein (intravenously)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Or </strong>under the skin (subcutaneously).</p><p>Your doctor will decide how Binocrit will be injected. Usually the injections will be given to you by a doctor, nurse or other health care professional. Some people, depending on why they need Binocrit treatment, may later learn how to inject themselves under the skin: see <em>Instructions on how to inject Binocrit yourself </em>at the end of the leaflet.</p><p>&nbsp;</p><p>Binocrit should not be used:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; after the expiry date on the label and outer carton</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you know, or think that it may have been accidentally frozen, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if there has been a refrigerator failure.</p><p>The dose of Binocrit you receive is based on your body weight in kilograms. The cause of your anaemia is also a factor in your doctor deciding the correct dose.</p><p>&nbsp;</p><p><strong>Your doctor will monitor your blood pressure </strong>regularly while you are using Binocrit.</p><p>&nbsp;</p><p><strong>People with kidney disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will maintain your haemoglobin level between 10 and 12 g/dl as a high haemoglobin level may increase the risk of blood clots and death. In children the haemoglobin level should be maintained between&nbsp;9.5&nbsp;and&nbsp;11&nbsp;g/dL.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The usual starting dose </strong>of Binocrit for adults and children is 50 International Units (IU) per kilogram (/kg) of body weight given three times a week. For patients on peritoneal dialysis Binocrit may be given twice a week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; For adults and children Binocrit is given as an injection either into a vein (intravenously) or a tube that goes into a vein. When this access (via a vein or tube) is not readily available, your doctor may decide that Binocrit should be injected under the skin (subcutaneously). This includes patients on dialysis and patients not yet on dialysis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will order regular blood tests to see how your anaemia is responding and may adjust the dose, usually no more frequently than every four weeks. A rise in haemoglobin of greater than&nbsp;2&nbsp;g/dL over a four week period should be avoided.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Once your anaemia has been corrected, your doctor will continue to check your blood regularly. Your Binocrit dose and frequency of administration may be further adjusted to maintain your response to treatment. Your doctor will use the lowest effective dose to control the symptoms of your anaemia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you do not respond adequately to Binocrit, your doctor will check your dose and will inform you if you need to change doses of Binocrit.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are on a more extended dosing interval (greater than once weekly) of Binocrit, you may not maintain adequate haemoglobin levels and you may require an increase in Binocrit dose or frequency of administration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You may be given iron supplements before and during Binocrit treatment to make it more effective.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are having dialysis treatment when you begin treatment with Binocrit, your dialysis regime may need to be adjusted. Your doctor will decide this.</p><p>&nbsp;</p><p><strong>Adults on chemotherapy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may initiate treatment with Binocrit if your haemoglobin is 10 g/dl or less.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will maintain your haemoglobin level between 10 and 12 g/dl as a high haemoglobin level may increase the risk of blood clots and death.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose is <strong>either </strong>150 IU per kilogram body weight three times a week <strong>or </strong>450 IU per kilogram body weight once a week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Binocrit is given by injection under the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will order blood tests, and may adjust the dose, depending on how your anaemia responds to Binocrit treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You may be given iron supplements before and during Binocrit treatment to make it more effective.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You will usually continue Binocrit treatment for one month after the end of chemotherapy.</p><p>&nbsp;</p><p><strong>Adult<em>s </em>donating their own blood</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The usual dose </strong>is 600 IU per kilogram body weight twice a week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Binocrit is given by injection into a vein immediately after you have donated blood for 3 weeks before your surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You may be given iron supplements before and during Binocrit treatment to make it more effective.</p><p>&nbsp;</p><p><strong>Adults scheduled for major orthopaedic surgery</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The recommended dose </strong>is 600 IU per kilogram body weight once a week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Binocrit is given by injection under the skin each week for three weeks before surgery and on the day of surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If there is a medical need to reduce the time before your operation, you will be given a daily dose of 300 IU/kg for up to ten days before surgery, on the day of surgery and for four days immediately afterwards.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If blood tests show your haemoglobin is too high before the operation, the treatment will be stopped.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You may be given iron supplements before and during Binocrit treatment to make it more effective.</p><p>&nbsp;</p><p><strong>Adults with myelodysplastic syndrome</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may initiate treatment with Binocrit if your haemoglobin is 10 g/dl or less. The aim of treatment is to maintain your haemoglobin level between 10 and 12 g/dl as a higher haemoglobin level may increase the risk of blood clots and death.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Binocrit is given by injection under the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose is 450 IU per kilogram bodyweight once a week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will order blood tests, and may adjust the dose, depending on how your anaemia responds to Binocrit treatment.</p><p>&nbsp;</p><p><strong>Instructions on how to inject Binocrit yourself</strong></p><p>When treatment starts, Binocrit is usually injected by a medical professional or a nurse. Later, your doctor may suggest that you or your caregiver learn how to inject Binocrit under the skin (<em>subcutaneously</em>) yourself.</p><p>&nbsp;</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not attempt to inject yourself unless you have been trained to do so by your doctor or nurse.</strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Always use Binocrit exactly as instructed by your doctor or nurse.</strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Ensure that you only inject the amount of liquid as instructed by your doctor or nurse.</strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only use Binocrit if it has been stored correctly &ndash; see section 5<em>, How to store Binocrit.</em></strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Before use, leave the Binocrit syringe to stand until it reaches room temperature. This usually takes between 15 and 30 minutes. Use the syringe within 3 days of taking it out of the refrigerator.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Only take one dose of Binocrit from each syringe.</strong></p><p>If Binocrit is injected under the skin (subcutaneously), the amount injected is not normally more than one millilitre (1 ml) in a single injection.</p><p>&nbsp;</p><p>Binocrit is given alone and not mixed with other liquids for injection.</p><p>&nbsp;</p><p><strong>Do not shake Binocrit syringes. </strong>Prolonged vigorous shaking may damage the product. If the product has been shaken vigorously, don&rsquo;t use it.</p><p>&nbsp;</p><p>Instructions on how to inject yourself with Binocrit can be found at the end of this leaflet.</p><p>&nbsp;</p><p><strong>If you use more Binocrit than you should</strong></p><p>Tell your doctor or nurse immediately if you think too much Binocrit has been injected. Side effects from an overdose of Binocrit are unlikely.</p><p>&nbsp;</p><p><strong>If you forget to use Binocrit</strong></p><p>Make the next injection as soon as you remember. If you are within a day of your next injection, forget the missed one and carry on with your normal schedule. Do not double up the injections.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor, nurse or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Tell your doctor or nurse immediately </strong>if you notice any of the effects in this list.</p><p><u>Very common side effects</u></p><p>These may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Feeling sick in your stomach</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vomiting</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Fever</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Respiratory tract congestion</strong>, such as stuffy nose and sore throat, has been reported in patients with kidney disease not yet on dialysis.</p><p>&nbsp;</p><p><u>Common side effects</u></p><p>These may affect up to 1 in 10 people</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Increased blood pressure</strong>. <strong>Headaches</strong>, particularly sudden, stabbing migraine-like headaches, <strong>feeling confused or having fits </strong>may be signs of a sudden increase in blood pressure. This requires urgent treatment. Raised blood pressure may require treatment with medicines (or adjustment to any medicines you already take for high blood pressure).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood clots </strong>(including deep vein thrombosis and embolism) that may require urgent treatment. You may have <strong>chest pain, breathlessness, and painful swelling and redness, usually in the leg </strong>as symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin rashes, which may result from an allergic reaction.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Bone or muscle pain.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Flu-like symptoms</strong>, such as headache, aches and pains in the joints, feeling of weakness, chills, tiredness and dizziness. These may be more common at the start of treatment. If you have these symptoms during injection into the vein, a slower delivery of the injection may help to avoid them in the future.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness, burning and pain at the site of injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Swelling of the ankles, feet or fingers.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Arm or leg pain.</strong></p><p><u>Uncommon side effects</u></p><p>These may affect up to 1 in 100 people</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>High levels of blood potassium </strong>which can cause abnormal heart rhythm (this is a very common side effect in patients on dialysis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fits.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Nose or airway congestion.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Allergic reaction.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hives.</strong></p><p><u>Rare side effects</u></p><p>These may affect up to 1 in 1,000 people</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Symptoms of pure red cell aplasia (PRCA)</p><p>PRCA means the bone marrow does not make enough red blood cells. PRCA causes <strong>sudden and severe anaemia. The symptoms are:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual tiredness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>feeling dizzy,</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>breathlessness.</strong></p><p>PRCA has been very rarely reported mostly in patients with kidney disease after months to years of treatment with epoetin alfa and other products that stimulate red blood cell production.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in levels of small blood cells (called platelets), which are normally involved in the formation of a blood clot may occur, particularly when starting treatment. Your doctor will check on this.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic reaction that may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a swollen face, lips, mouth, tongue or throat,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty swallowing or breathing,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy rash (hives).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problem with the blood that may cause pain, dark coloured urine or increased sensitivity of the skin to sunlight (porphyria).</p><p>&nbsp;</p><p>If you are receiving haemodialysis:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood clots </strong>(thrombosis) may form in your dialysis shunt. This is more likely if you have low blood pressure or if your fistula has complications.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood clots </strong>may also form in your haemodialysis system. Your doctor may decide to increase your heparin dose during dialysis.</p><p>&nbsp;</p><p>Serious skin rashes including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in association with epoetin treatment. These can appear as reddish target-like macules or circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and can be preceded by fever and flu-like symptoms. Stop using Binocrit if you develop these symptoms and contact your doctor or seek medical attention immediately. See also section 2.</p><p>&nbsp;</p><p><strong>Tell your doctor or nurse immediately </strong>if you are aware of any of these effects, or if you notice any other effects while you are receiving treatment with Binocrit<strong>.</strong></p><p><strong>&nbsp;</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the label and carton after EXP.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store and transport refrigerated (2&deg;C-8&deg;C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may take Binocrit out of the refrigerator and keep it at room temperature (up to 25&deg;C) for no longer than 3 days. Once a syringe has been removed from the refrigerator and has reached room temperature (up to 25&deg;C) it must either be used within 3 days or disposed of.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze or shake.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from light.</p><p>Do not use this medicine if you notice that</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; it may have been accidentally frozen, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if there has been a refrigerator failure,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; the liquid is coloured or you can see particles floating in it,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; the seal is broken.</p><p><strong>Do not throw away any medicines via wastewater or household waste. </strong>Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Binocrit contains</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The active substance is</strong>: epoetin alfa (for quantity see the table below).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The other ingredients are: sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, sodium chloride, glycine, polysorbate&nbsp;80, hydrochloric acid (for pH‑adjustment), sodium hydroxide (for pH‑adjustment), and water for injections.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Binocrit is presented as a clear, colourless solution for injection in a pre-filled syringe. The syringes are sealed in a blister.

Presentation	Corresponding Presentations in Quantity/Volume for each Strength	Amount of epoetin alfa
Pre-filled syringes*	                                     2,000 IU/ml:	
	                                                                      1,000 IU/0.5 ml	                                                         8.4 micrograms
	                                                                      2,000 IU/1 ml	                                                                 16.8 micrograms
	                                                                     10,000 IU/ml:	
	                                                                     4,000 IU/0.4 ml	                                                      33.6 micrograms
	                                                                    10,000 IU/1 ml	                                                             84.0 micrograms
	                                                                  40,000 IU/ml:	
	                                                                    20,000 IU/0.5 ml	                                                  168.0 micrograms
	                                                                     30,000 IU/0.75 ml	                                                  252.0 micrograms
	                                                                    40,000 IU/1 ml	                                                          336.0 micrograms
*Pack size of 1, 4 or 6 pre-filled syringe(s) with or without a needle safety guard. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Sandoz GmbH Biochemiestr. 10 A-6250 Kundl Austria</p><p>&nbsp;</p><p><strong>&nbsp; Drug Product Manufacturer</strong></p><p>&nbsp;</p><p>&nbsp;&nbsp; IDT Biologika GmbH</p><p>&nbsp; &nbsp;Am Pharmapark</p><p>&nbsp;&nbsp; 06861 Dessau-Rosslau</p><p>&nbsp;&nbsp; Germany</p><p>&nbsp;</p><p><strong>Batch Releaser</strong></p><p>Sandoz GmbH Biochemiestr. 10</p><p>A-6336 Langkampfen Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي بينوكريت على المادة الفعالة إيبويتين ألفا، بروتين يحفّز النخاع العظمي على إنتاج المزيد من كريات الدم الحمراء التي تحمل الهيموغلوبين (مادة تنقل الأكسجين). إيبويتين ألفا هو نسخة من بروتين الإريثروبويتين البشري وتنشط بالطريقة نفسها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستعمل بينوكريت لعلاج فقر الدم المصحوب بأعراض والناجم عن مرض الكلى:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لدى الأطفال الذين يخضعون للغسيل الدموي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لدى البالغين الذين يخضعون للغسيل الدموي أو الغسيل البريتوني</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لدى البالغين المصابين بفقر دم حاد ولم يخضعوا للغسيل الكلوي بعد</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال كنت مصابًا بمرض الكلى، قد تعاني نقصًا في كريات الدم الحمراء إذا كانت الكليتان لديك لا تنتجان ما يكفي من الإريثروبويتين (ضروري لإنتاج الكريات الحمراء). يوصف بينوكريت لتحفيز النخاع العظمي على إنتاج المزيد من كريات الدم الحمراء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستعمل بينوكريت لعلاج حالة فقر الدم لدى البالغين الذين يتلقون العلاج الكيميائي نتيجة الإصابة بأورام صلبة</strong> أو سرطان الغدد الليمفاوية الخبيث أو ورم نقوي متعدد (سرطان النخاع العظمي) والذين قد يحتاجون إلى عملية نقل دم. يمكن أن يقلل بينوكريت من الحاجة إلى عملية نقل الدم لدى هؤلاء المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستعمل بينوكريت لعلاج البالغين المصابين بفقر الدم المعتدل الذين يتبرعون ببعض من دمهم قبل الجراحة،</strong> بحيث يمكنهم الحصول عليه من جديد في أثناء العملية الجراحية أو بعدها. ونظرًا إلى أن بينوكريت يحفّز على إنتاج كريات الدم الحمراء، يمكن أن يأخذ الأطباء كميات أكثر من الدم من هؤلاء الأشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستعمل بينوكريت لدى البالغين المصابين بفقر الدم المعتدل الذين على وشك الخضوع لجراحة عظام كبيرة</strong> (على سبيل المثال عمليات استبدال الورك أو الركبة)، بهدف تقليل احتمالية الحاجة إلى عمليات نقل الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستعمل بينوكريت لعلاج فقر الدم </strong><strong>لدى المرضى الكبار المصابين باضطراب &nbsp;نخاخ العظم الذي يسبب اضطرابا شديدا في انشاء خلايا الدم</strong><strong> (بمتلازمة خلل التنسج النقوي).</strong> يمكن أن يقلل بينوكريت من الحاجة إلى عملية نقل الدم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل بينوكريت:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني حساسية</strong> تجاه إيبويتين ألفا أو أي من المكونات الأخرى لهذا الدواء (الواردة في القسم 6).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا تم تشخيص إصابتك بحالة عدم تنسج الكرية الحمراء النقي</strong> (عدم قدرة النخاع العظمي على إنتاج ما يكفي من كريات الدم الحمراء) بعد الخضوع لعلاج سابق بأي منتجات تعمد إلى تحفيز إنتاج كريات الدم الحمراء (ومنها بينوكريت).<br />راجع القسم 4.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني ارتفاع ضغط الدم</strong> الذي لم يتم التحكم به كما ينبغي عن طريق الأدوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لتحفيز إنتاج كريات <strong>الدم</strong> الحمراء لديك (بحيث يتمكن الأطباء من أخذ كميات أكثر من الدم منك)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا لم تستطع إجراء عمليات نقل لدمك</strong> في أثناء الجراحة أو <strong>بعدها</strong>.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت على وشك الخضوع لجراحة عظام انتقائية كبيرة</strong> (مثل جراحة الورك أو الركبة) وكنت:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مصابًا بمرض قلب شديد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني اضطرابات شديدة في الأوردة والشرايين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تعرّضت مؤخرًا لأزمة قلبية أو سكتة دماغية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم تستطع تناول أدوية للتخفيف من كثافة الدم</p><p dir="RTL">قد لا يكون بينوكريت مناسبًا لك. الرجاء مناقشة الأمر مع طبيبك. في أثناء استعمال بينوكريت، قد يحتاج بعض الأشخاص إلى أدوية لتقليل خطر الإصابة بجلطات دموية. <strong>إذا كنت لم تستطع تناول الأدوية التي تمنع تجلط الدم، فيُحظّر عليك استعمال بينوكريت.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والتدابير الوقائية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استعمال بينوكريت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد يزيد بينوكريت وغيره من المنتجات التي تحفّز على إنتاج الكريات الحمراء من خطر الإصابة بجلطات دموية لدى كل المرضى.</strong><strong> قد يزيد خطر الإصابة في حال توفرت لديك عوامل خطر أخرى</strong> تسهم في حدوث جلطات دموية <em>(على سبيل المثال، إذا أُصبت بجلطة دموية سابقًا أو كنت تعاني من زيادة الوزن أو من داء السكري أو مرض القلب أو كنت أسير الفراش لفترة طويلة بسبب خضوعك لجراحة أو إصابتك بمرض)</em>.</p><p dir="RTL">يُرجى إبلاغ طبيبك في حال لاحظت أيًّا من هذه الأعراض. سيساعدك طبيبك على تحديد ما إذا كان بينوكريت مناسبًا لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>من المهم إبلاغ طبيبك</strong> في حال انطبقت عليك أي من الحالات الآتية. قد لا يزال بإمكانك استعمال بينوكريت، لكن عليك مناقشة الأمر مع طبيبك أولاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال كنت تعلم أنك تعاني</strong> أو سبق أن عانيت أيًا مما يأتي:</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ارتفاع ضغط الدم.</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نوبات الصرع.</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مرض الكبد.</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>فقر الدم الناجم عن أسباب أخرى.</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>البورفيريا (اضطراب نادر في الدم).</strong></p><p dir="RTL"><strong>إذا كنت مريضًا بالسرطان</strong>، فانتبه إلى أن المنتجات التي تحفّز على إنتاج كريات الدم الحمراء (مثل بينوكريت) قد تعمل كعامل نموّ، ومن ثمَّ يفترض أن تؤثر في تقدّم حالة إصابتك بالسرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تبعًا لحالتك الفردية، قد يفضل إجراء عملية نقل للدم.</strong><strong> الرجاء مناقشة هذا الأمر مع طبيبك.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت مريضًا مصابًا بالتهاب الكبد من النوع </strong><strong>C وتخضع لعلاج إنترفيرون وريبافيرين</strong>، فعليك مناقشة هذا الأمر مع طبيبك؛ حيث أدى الجمع بين إيبويتين ألفا وإنترفيرون وريبافيرين في حالات نادرة إلى فقدان مفعول الدواء والإصابة بحالة عدم تنسج الكرية الحمراء النقي، وهي أحد أشكال فقر الدم الحاد. لم تتم الموافقة على استعمال بينوكريت في علاج فقر الدم المرتبط بالتهاب الكبد من النوع C.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت مريضًا مصابًا بفشل كلوي مزمن</strong>، ولا تستجيب بشكل خاص لدواء بينوكريت كما ينبغي، فسيتحقق طبيبك من جرعة بينوكريت الموصوفة لك؛ لأن زيادة جرعتك من بينوكريت بشكل متكرر في حال كنت لا تستجيب للعلاج قد تزيد من خطر الإصابة بمشكلة في القلب أو الأوعية الدموية وقد تزيد من خطر الإصابة بذبحة قلبية أو سكتة دماغية أو الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت مريضًا بالسرطان،</strong> فانتبه إلى أن استعمال بينوكريت قد يرتبط بانخفاض معدل البقاء على قيد الحياة وارتفاع معدل الوفاة لدى المرضى المصابين بسرطان الرأس والعنق وسرطان الثدي النَّقيلِيّ والذين يخضعون للعلاج الكيميائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كن حريصًا عند استعمال منتجات أخرى تحفّز على إنتاج كريات الدم الحمراء:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">بينوكريت عبارة عن مجموعة من المنتجات التي تحفّز على إنتاج كريات الدم الحمراء تمامًا مثلما يحفّز بروتين الإريثروبويتين البشري ذلك. دائمًا ما سيسجّل متخصص الرعاية الصحية المتابع لحالتك المنتج الذي تستعمله بالضبط. إذا تم إعطاؤك منتجًا من هذه المجموعة بخلاف بينوكريت في أثناء العلاج، فتحدث إلى طبيبك أو الصيدلي قبل استعماله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كن حريصًا عند استعمال بينوكريت:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تم تسجيل <strong>تفاعلات جلدية خطيرة</strong>، بما فيها متلازمة ستيفنز جونسون (SJS) وتقشر الأنسجة المتموتة البشروية التسممي ((TEN، عند العلاج بإيبويتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تظهر علامات متلازمة ستيفنز جونسون/تقشر الأنسجة المتموتة البشروية التسممي في البداية على هيئة بقع حمراء تشبه أقراص رمي السهم أو رقعًا دائرية، وغالبًا ما تكون مصحوبة ببثور في الوسط عند ظهورها على الجذع. وقد تحدث أيضًا تقرحات في الفم والحلق والأنف والأعضاء التناسلية والعينين (عينان حمراوان ومتورمتان). غالبًا ما تسبق حالات الطفح الجلدي الخطير هذه حمّى و/أو أعراض شبيهة بأعراض الإنفلونزا. قد تزداد حالات الطفح الجلدي، ما يؤدي إلى تقشير منطقة كبيرة من الجلد والإصابة بمضاعفات مهددة للحياة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال إصابتك بطفح جلدي خطير أو أي من أعراض الجلد هذه، توقف عن استعمال بينوكريت واتصل بطبيبك أو التمس رعاية طبية على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى مع بينوكريت</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;أخبرطبيبك اذا كنت تتناول أو تناولت مؤخرا أو قد تتناول ي أدوية أخرى.</p><p dir="RTL"><strong>إذا كنت تتناول دواءً اسمه سيكلوسبورين</strong> (يتم استعماله مثلاً بعد عمليات زرع الكلى)، فقد يطلب طبيبك فحوصات دم للتحقق من مستوى السيكلوسبورين عند تناوله مع بينوكريت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تزيد <strong>مكملات الحديد ومحفزات الدم الأخرى</strong> من فعالية بينوكريت. سيقرر طبيبك ما إذا كان من المناسب أن تستعمله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا زرت مستشفى أو عيادة أو طبيب عائلة</strong>، فمن المهم الإبلاغ بأنك تستعمل علاج بينوكريت. فقد يؤثر في العلاجات الأخرى أو نتائج الفحوصات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>من المهم إبلاغ طبيبك</strong> في حال انطبقت عليك أي من الحالات الآتية. قد لا يزال بإمكانك استعمال بينوكريت، لكن عليك مناقشة الأمر مع طبيبك أولاً:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنتِ حاملاً</strong> أو تعتقدين أنكِ قد تكونين حاملاً.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنتِ تقومين بالرضاعة الطبيعية.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي بينوكريت على الصوديوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي بينوكريت على أقل من ١ مليمول (٢٣ مليغرامًا) من الصوديوم في كل جرعة، بمعنى أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استعمل هذا الدواء دائمًا على النحو الذي وصفه لك طبيبك. تحقق من طبيبك إذا لم تكن متأكدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أجرى طبيبك فحوصات الدم</strong> وقرر أنك بحاجة إلى بينوكريت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعطاء بينوكريت عن طريق الحقن:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إما</strong> في الوريد أو في أنبوب يتم إدخاله في الوريد (حقنة داخل الوريد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أو</strong> تحت الجلد (حقنة تحت الجلد).</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيبك كيف سيتم حقن بينوكريت. عادةً ما يقوم طبيب أو ممرضة أو متخصص رعاية صحية آخر بإعطائك جرعات الحقن. قد يتعلّم لاحقًا بعض الأشخاص، حسب حاجتهم إلى علاج بينوكريت، كيفية حقن أنفسهم تحت الجلد: راجع <em>التعليمات حول كيفية حقن دواء بينوكريت بنفسك</em> في نهاية النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم استعمال بينوكريت في الحالات الآتية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد مرور تاريخ انتهاء الصلاحية المدوَّن على الملصق والعلبة الخارجية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعرف أو تعتقد أنه تم تجميد الدواء عن طريق الخطأ.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت الثلاجة لا تعمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعتمد جرعة بينوكريت التي تتلقاها على وزنك بالكيلوغرام. يشكّل سبب فقر الدم الذي تعاني منه عاملاً أيضًا يستند إليه طبيبك عند تحديد الجرعة المناسبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سيراقب طبيبك ضغط دمك</strong> بانتظام بينما تخضع لعلاج بينوكريت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأشخاص المصابون بمرض الكلى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيعمل طبيبك على الحفاظ على مستوى الهيموغلوبين لديك بين ١٠ و١٢ غم/ديسيلتر؛ فقد يزيد مستوى الهيموغلوبين المرتفع من خطر الإصابة بجلطات دموية والوفاة.عند الأطفال ,يجب الحفاظ على مستوى الهيموغلوبين بين 5,9 و11غم/ديسيلتر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ <strong>الجرعة الأولية المعتادة</strong> من بينوكريت لدى البالغين والأطفال ٥٠ وحدة دولية لكل كيلوغرام (كغم) من وزن الجسم ويتم إعطاؤها ثلاث مرات في الأسبوع. بالنسبة إلى المرضى الذين يخضعون للغسيل البريتوني، يمكن إعطاء بينوكريت مرتين في الأسبوع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة إلى البالغين والأطفال، يتم إعطاء بينوكريت عن طريق الحقن إما في الوريد (حقنة داخل الوريد) أو في أنبوب يتم إدخاله في الوريد. عندما لا يتوفر هذا المأتى (عبر الوريد أو الأنبوب) بسهولة، قد يقرر طبيبك حقن بينوكريت تحت الجلد (حقنة تحت الجلد). ويشمل ذلك المرضى الذين يخضعون للغسيل الكلوي والمرضى الذين لم يخضعوا للغسيل الكلوي بعد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيطلب طبيبك فحوصات دم بانتظام لمعرفة مدى استجابة فقر الدم الذي تعاني منه وقد يعدّل الجرعة، وغالبًا ما يتم ذلك بوتيرة لا تزيد على مرة كل أربعة أسابيع.ينبغي تجنب زيادة الهيموغلوبين عن 2 غم/ديسيلترخلال فترة أربعة أسابيع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بمجرد علاج فقر الدم الذي تعاني منه، سيتابع طبيبك فحص دمك بانتظام. يمكن تعديل جرعة بينوكريت التي تأخذها وعدد مرات حقنها مرة أخرى للحفاظ على استجابتك للعلاج. سيستعمل طبيبك أدنى جرعة فعالة للتحكم في أعراض فقر الدم الذي تعاني منه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تستجب كما يجب لعلاج بينوكريت، فسيتحقق طبيبك من جرعتك ويعلمك بما إذا كنت بحاجة إلى تغيير جرعات بينوكريت.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تلتزم بفاصل زمني ممتد لفترة طويلة (أكثر من مرة في الأسبوع) لحقن بينوكريت، فقد لا تنجح في الحفاظ على مستويات الهيموغلوبين المناسبة وقد يتعين عليك زيادة جرعة بينوكريت أو عدد مرات حقنها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتم إعطاؤك مكملات الحديد قبل علاج بينوكريت وفي أثنائه لجعله أكثر فعالية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع لعلاج الغسيل الكلوي عند بدء العلاج بدواء بينوكريت، فقد يتعيّن عليك تعديل نظام الغسيل الكلوي. سيقرر طبيبك هذا الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون الخاضعون للعلاج الكيميائي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يبدأ طبيبك بعلاج بينوكريت في حال كان مستوى الهيموغلوبين لديك ١٠ غم/ديسيلتر أو أقل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيعمل طبيبك على الحفاظ على مستوى الهيموغلوبين لديك بين ١٠ و١٢ غم/ديسيلتر؛ فقد يزيد مستوى الهيموغلوبين المرتفع من خطر الإصابة بجلطات دموية والوفاة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة الأولية <strong>إما</strong> ١٥٠ وحدة دولية لكل كيلوغرام من وزن الجسم ويتم حقنها ثلاث مرات في الأسبوع <strong>أو</strong> ٤٥٠ وحدة دولية لكل كيلوغرام من وزن الجسم ويتم حقنها مرة في الأسبوع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء بينوكريت عن طريق حقنه تحت الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيطلب طبيبك فحوصات دم، وقد يعدل الجرعة، تبعًا لمدى استجابة فقر الدم الذي تعاني منه لعلاج بينوكريت.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتم إعطاؤك مكملات الحديد قبل علاج بينوكريت وفي أثنائه لجعله أكثر فعالية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستستمر عادةً في علاج بينوكريت لمدة شهر واحد بعد نهاية العلاج الكيميائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون المتبرّعون بدمهم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ <strong>الجرعة المعتادة</strong> ٦٠٠ وحدة دولية لكل كيلوغرام من وزن الجسم ويتم حقنها مرتين في الأسبوع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء بينوكريت عن طريق حقنه في الوريد مباشرةً بعد تبرعك بالدم لمدة ٣ أسابيع قبل خضوعك للجراحة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتم إعطاؤك مكملات الحديد قبل علاج بينوكريت وفي أثنائه لجعله أكثر فعالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون المقرر خضوعهم لجراحة عظام كبيرة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ <strong>الجرعة الموصى بها</strong> ٦٠٠ وحدة دولية لكل كيلوغرام من وزن الجسم ويتم حقنها مرة في الأسبوع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء بينوكريت عن طريق حقنه تحت الجلد كل أسبوع لمدة ثلاثة أسابيع قبل موعد الجراحة وفي يوم الجراحة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال دعت حاجة طبية إلى تقليل المدة قبل العملية، سيتم إعطاؤك جرعة يومية مقدارها ٣٠٠ وحدة دولية/كغم لمدة تصل إلى عشرة أيام قبل موعد الجراحة وفي يوم الجراحة ولمدة أربعة أيام بعد العملية الجراحية على الفور.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أظهرت فحوصات الدم أن مستوى الهيموغلوبين لديك مرتفع جدًا قبل العملية، فسيتم إيقاف العلاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتم إعطاؤك مكملات الحديد قبل علاج بينوكريت وفي أثنائه لجعله أكثر فعالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون المصابون بمتلازمة خلل التنسج النقوي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يبدأ طبيبك بعلاج بينوكريت في حال كان مستوى الهيموغلوبين لديك ١٠ غم/ديسيلتر أو أقل. يهدف العلاج إلى الحفاظ على مستوى الهيموغلوبين لديك بين ١٠ و١٢ غم/ديسيلتر؛ فقد يزيد مستوى الهيموغلوبين المرتفع من خطر الإصابة بجلطات دموية والوفاة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء بينوكريت عن طريق حقنه تحت الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة الأولية ٤٥٠ وحدة دولية لكل كيلوغرام من وزن الجسم ويتم حقنها مرة في الأسبوع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيطلب طبيبك فحوصات دم، وقد يعدل الجرعة، تبعًا لمدى استجابة فقر الدم الذي تعاني منه لعلاج بينوكريت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات حول كيفية حقن دواء بينوكريت بنفسك</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما يبدأ العلاج، عادةً ما يُحقن بينوكريت على يدَي اختصاصي طبي أو ممرضة. في مرحلة لاحقة، قد يقترح طبيبك عليك أن تتعلّم أنت أو مقدم الرعاية الخاص بك كيفية حقن بينوكريت تحت الجلد (<em>حقنة تحت الجلد</em>) بنفسك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا تحاول الحقن بنفسك إلا إذا كنت مدربًا على ذلك على يد طبيبك أو الممرضة.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>استعمل بينوكريت دائمًا حسب تعليمات طبيبك أو الممرضة.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تأكد من حقن كمية السائل حسب تعليمات طبيبك أو الممرضة فقط.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تستعمل بينوكريت إلا إذا كان مخزنًا بشكل صحيح &ndash; راجع القسم 5، <em>كيفية تخزين بينوكريت</em>.</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>قبل الاستخدام، اترك محقنة بينوكريت جانبًا حتى تصل درجة حرارتها إلى درجة حرارة الغرفة.</strong><strong> عادةً ما يستغرق ذلك من ١٥ إلى٣٠ دقيقة.</strong><strong> استخدم المحقنة خلال ٣ أيام من تاريخ إخراجها من الثلاجة.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قم بحقن جرعة بينوكريت واحدة فقط من كل محقنة.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم حقن بينوكريت تحت الجلد (حقنة تحت الجلد)، فلا تزيد الكمية المحقونة عادة على مليلتر واحد (١ مل) في جرعة حقن واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء بينوكريت وحده ولا يتم خلطه مع سوائل أخرى للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا ترجّ محاقن بينوكريت.</strong><strong> </strong>قد يتسبب الرجّ بشدة ولفترة طويلة في تلف المنتج. في حال رجّ المنتج بشدة، لا تستخدمه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن العثور على تعليمات حول كيفية حقن دواء بينوكريت بنفسك في نهاية هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال الإفراط في استعمال بينوكريت</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الممرضة على الفور إذا كنت تعتقد أنه تم الإفراط في حقن بينوكريت. لا يحتمل حدوث آثار جانبية نتيجة حقن جرعة زائدة من بينوكريت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال نسيت حقن بينوكريت</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكنك أخذ الجرعة التالية من الحقن حالما تتذكر. إذا حان يوم حقنك التالي، فتجاهل الجرعة المنسية وتابع جدولك المعتاد. لا تضاعف جرعات الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أسئلة أخرى حول استخدام هذا المنتج، فاسأل طبيبك أو الممرضة أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كغيره من الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو الممرضة على الفور</strong> إذا لاحظت أيًا من الآثار المذكورة في هذه القائمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الآثار الجانبية الشائعة جدًا</u></p><p dir="RTL">قد تصيب هذه الآثار أكثر من شخص واحد من أصل ١٠ أشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الإسهال</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الشعور بالغثيان</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التقيؤ</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الحمّى</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم تسجيل حالات <strong>احتقان الجهاز التنفسي</strong>، مثل سيلان الأنف واحتقان الحلق، لدى المرضى المصابين بمرض الكلى الذين لم يخضعوا للغسيل الكلوي بعد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الآثار الجانبية الشائعة</u></p><p dir="RTL">قد تصيب هذه الآثار شخصًا واحدًا من أصل ١٠ أشخاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ارتفاع ضغط الدم</strong>. قد تكون <strong>آلام الرأس</strong>، ولا سيما آلام الرأس المفاجئة والمؤلمة الشبيهة بأوجاع الصداع النصفي، أو الشعور <strong>بالارتباك أو التعرّض للنوبات</strong> علامات على ارتفاع مفاجئ في ضغط الدم. يتطلب ذلك علاجًا طارئًا. قد يتطلب ارتفاع ضغط الدم علاجًا بالأدوية (أو تعديل أي أدوية تتناولها عادةً لعلاج ارتفاع ضغط الدم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجلطات الدموية</strong> (بما فيها التخثر الوريدي العميق والانصمام) التي قد تتطلب علاجًا طارئًا. قد تظهر أعراض مثل <strong>ألم الصدر وضيق التنفس والتورم المؤلم والاحمرار، وغالبًا ما تصيب الساق</strong>.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>السعال.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الطفح الجلدي الذي قد ينجم عن رد فعل تحسسي.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ألم في العظام أو العضلات.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أعراض شبيهة بأعراض الإنفلونزا</strong>، مثل الصداع وآلام وأوجاع في المفاصل والشعور بالضعف والقشعريرة والتعب والدوار. وقد تكون هذه الأعراض أكثر شيوعًا في بداية العلاج. إذا أُصبت بهذه الأعراض في أثناء الحقن في الوريد، فقد يساعد إبطاء سرعة الحقن على تفادي حدوث ذلك في المستقبل.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحمرار والشعور بحرقان وألم في موضع الحقن.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تورّم الكاحلين أو القدمين أو الأصابع.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ألم في الذراعين أو الساقين.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الآثار الجانبية غير الشائعة</u></p><p dir="RTL">قد تصيب هذه الآثار شخصًا واحدًا من أصل ١٠٠ شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ارتفاع مستويات البوتاسيوم في الدم</strong>، ما قد يتسبب في خلل نظم القلب (هذا الأثر الجانبي شائع جدًا لدى المرضى الذين يخضعون للغسيل الكلوي).</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>النوبات.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>احتقان الأنف أو المسلك الهوائي.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>رد فعل تحسسي.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الشرى.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الآثار الجانبية النادرة</u></p><p dir="RTL">قد تصيب هذه الآثار شخصًا واحدًا من أصل ١٠٠٠ شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>أعراض عدم تنسج الكرية الحمراء النقي (</strong><strong>PRCA)</strong></p><p dir="RTL">يشير مصطلح عدم تنسج الكرية الحمراء النقي إلى أن النخاع العظمي لا ينتج ما يكفي من كريات الدم الحمراء. تتسبب حالة عدم تنسج الكرية الحمراء النقي في الإصابة <strong>بفقر دم مفاجئ وشديد.</strong><strong> في ما يأتي الأعراض:</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التعب غير المعتاد،</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الشعور بالدوار،</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ضيق التنفس.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تم تسجيل عدم تنسج الكرية الحمراء النقي في حالات نادرة جدًا أغلبها لدى المرضى المصابين بمرض الكلى بعد مرور أشهر إلى سنوات من العلاج بإيبويتين ألفا وغيره من المنتجات التي تحفّز على إنتاج كريات الدم الحمراء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد ترتفع مستويات كريات الدم الصغيرة (المسمّاة بالصفيحات الدموية) التي عادةً ما تتسبب في تكوين جلطة دموية، ولا سيما عند بدء العلاج. سيتحقق طبيبك من هذا الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتضمن ردود الفعل التحسسية الشديدة:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّمًا في الوجه أو الشفاه أو الفم أو اللسان أو الحلق،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع أو التنفس،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفحًا جلديًّا مثيرًا للحك (الشرى).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات الدم التي قد تتسبب في الألم أو تحوّل البول إلى لون داكن أو زيادة حساسية الجلد تجاه ضوء الشمس (البورفيريا).</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال خضوعك للغسيل الدموي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتكون <strong>جلطات دموية</strong> (تخثر) في تحويلة الغسيل الكلوي لديك. من المحتمل أن يحدث ذلك في حال انخفاض ضغط الدم لديك أو إذا تعرّضت النواسير لديك لمضاعفات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتكون <strong>جلطات دموية</strong> أيضًا في نظام الغسيل الدموي. قد يقرر طبيبك زيادة جرعة الهيبارين لك في أثناء الغسيل الكلوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم تسجيل حالات طفح جلدي خطيرة، بما فيها متلازمة ستيفنز جونسون وتقشر الأنسجة المتموتة البشروية التسممي، عند العلاج بإيبويتين. ويمكن أن تظهر علامات الطفح الجلدي على هيئة بقع حمراء تشبه أقراص رمي السهم أو رقعًا دائرية، وغالبًا ما تكون مصحوبة ببثور في الوسط عند ظهورها على الجذع أو تظهر على هيئة تقشرات في الجلد وتقرحات في الفم والحلق والأنف والأعضاء التناسلية والعينين، وقد تسبقها حمى وأعراض تشبه أعراض الإنفلونزا. توقف عن استعمال بينوكريت في حال ظهرت عليك هذه الأعراض وتواصل مع طبيبك أو التمس رعاية طبية على الفور. راجع أيضًا القسم 2.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو الممرض على الفور</strong> في حال لاحظت أيًا من هذه الآثار أو في حال لاحظتَ أي آثار أخرى في أثناء تلقّي علاج بينوكريت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال اشتدت خطورة أي من الآثار الجانبية أو في حال لاحظت أي آثار جانبية غير مذكورة في هذه النشرة، يُرجى إعلام طبيبك أو الممرضة أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بهذا الدواء بعيدًا عن مرأى الأطفال ومتناولهم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المدوَّن على الملصق والعلبة بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ المنتج ويتم نقله مبرّدًا (بين ٢ و ٨ درجات مئوية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك إخراج بينوكريت من الثلاجة وتركه في درجة حرارة الغرفة (التي تصل إلى ٢٥&nbsp;درجة مئوية) لمدة لا تزيد على ٣ أيام. ما إن يتم إخراج المحقنة من الثلاجة وتبلغ درجة حرارة الغرفة (التي تصل إلى ۲٥&nbsp;درجة مئوية)، يجب حقنها في غضون ٣ أيام أو التخلص منها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب تجميد المنتج أو رجّه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُخزَّن في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظتَ الآتي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنه تم تجميده عن طريق الخطأ.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان هناك عطل في الثّلاجة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان السائل ملوّنًا أو كانت بإمكانك رؤية جسيمات طافية فيه.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت عبوةُ التغليف مفتوحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تلقِ أي أدوية في مياه الصرف أو الفضلات المنزلية.</strong><strong> </strong>اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. حيث تساعد تلك الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات بينوكريت</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المادة الفعالة هي:</strong> إيبويتين ألفا (لمعرفة الكمية، راجع الجدول أدناه).</p><p><strong>المكونات الأخرى هي:</strong> ثنائي هيدرات فوسفات ثنائي هيدروجين الصوديوم وثنائي هيدرات فوسفات ثنائي الصوديوم وكلوريد الصوديوم وغلايسين وبوليسوربات ٨٠ وحمض الهيدروكلوريك (لضبط درجة الحموضة) وهيدروكسيد الصوديوم (لضبط درجة الحموضة)، والماء لجرعات الحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشكل الخارجي لبينوكريت ومحتويات العبوة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">بينوكريت عبارة عن محلول صافٍ وعديم اللون للحقن في محقنة معبأة. وتكون المحقنات محكمة الغلق في علبة.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:0px"><thead><tr><td style="vertical-align:top"><p dir="RTL"><strong>الشكل الدوائي</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الأشكال الدوائية المقابلة حسب الكمية/الحجم لكل شدة مفعول للدواء</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>كمية إيبويتين ألفا</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p dir="RTL">المحقنات المعبأة<sup>*</sup></p></td><td style="vertical-align:top"><p dir="RTL"><u>٢٠٠٠ وحدة دولية/مل:</u></p></td><td style="vertical-align:top"><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">١٠٠٠ وحدة دولية/٠٫٥ مل</p></td><td style="vertical-align:top"><p dir="RTL">٨٫٤ ميكروغرامات</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">٢٠٠٠ وحدة دولية/١ مل</p></td><td style="vertical-align:top"><p dir="RTL">١٦٫٨ ميكروغرامًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL"><u>١٠٠٠٠ وحدة دولية/مل:</u></p></td><td style="vertical-align:top"><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">٤٠٠٠ وحدة دولية/٠٫٤ مل</p></td><td style="vertical-align:top"><p dir="RTL">٣٣٫٦ ميكروغرامًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">١٠٠٠٠ وحدة دولية/١ مل</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">٨٤٫٠ ميكروغرامًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL"><u>٤٠٠٠٠ وحدة دولية/مل:</u></p></td><td style="vertical-align:top"><p dir="LTR">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">٢٠٠٠٠ وحدة دولية/٠٫٥ مل</p></td><td style="vertical-align:top"><p dir="RTL">١٦٨٫٠ ميكروغرامًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">٣٠٠٠٠ وحدة دولية/٠٫٧٥ مل</p></td><td style="vertical-align:top"><p dir="RTL">٢٥٢٫٠ ميكروغرامًا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">٤٠٠٠٠ وحدة دولية/١ مل</p></td><td style="vertical-align:top"><p dir="RTL">٣٣٦٫٠ ميكروغرامًا</p></td></tr></tbody></table><p dir="RTL"><sup>*</sup>تحتوي العبوة على محقنة واحدة أو ٤ أو ٦ محاقن معبأة ومزودة بواقٍ للإبرة أو غير مزودة به. قد لا تتوافر كل أحجام العبوات في السوق.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب ترخيص التسويق</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">Sandoz GmbH</p><p dir="RTL">‪Biochemiestr. 10</p><p dir="RTL">A-6250 Kundl</p><p dir="RTL">النمسا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المُصنِّعة للمنتجات الدوائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">IDT Biologika GmbH</p><p dir="RTL">Am Pharmapark</p><p dir="RTL">Dessau-Rosslau06861</p><p dir="RTL">ألمانيا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المسؤولة عن إصدار التشغيلة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">Sandoz GmbH</p><p dir="RTL">‪Biochemiestr. 10</p><p dir="RTL">A-6336 Langkampfen</p><p dir="RTL">النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Binocrit 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Binocrit 2,000 IU/1 mL solution for injection in a pre-filled syringe 
Binocrit 4,000 IU/0.4 mL solution for injection in a pre-filled syringe Binocrit 10,000 IU/1 mL solution for injection in a pre-filled syringe Binocrit 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Binocrit 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Binocrit 40,000 IU/1 mL solution for injection in a pre-filled syringe


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Binocrit 1,000 IU/0.5 mLmL solution for injection in a pre-filled syringe
Each mL of solution contains 2,000 IU of epoetin alfa* corresponding to 16.8 micrograms per mL
A pre-filled syringe of 0.5 mL contains 1,000 international units (IU) corresponding to 8.4 micrograms epoetin alfa. *

Binocrit 2,000 IU/1 mL solution for injection in a pre-filled syringe
Each mL of solution contains 2,000 IU of epoetin alfa* corresponding to 16.8 micrograms per mL
A pre-filled syringe of 1 mL contains 2,000 international units (IU) corresponding to 16.8 micrograms epoetin alfa. *


Binocrit 4,000 IU/0.4 mL solution for injection in a pre-filled syringe
Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL A pre-filled syringe of 0.4 mL contains 4,000 international units (IU) corresponding to
33.6 micrograms epoetin alfa. *

Binocrit 10,000 IU/1 mL solution for injection in a pre-filled syringe
Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL
A pre-filled syringe of 1 mL contains 10,000 international units (IU) corresponding to 84.0 micrograms epoetin alfa. *

Binocrit 20,000 IU/0.5 mL solution for injection in a pre-filled syringe
Each mL of solution contains 40,000 IU of epoetin alfa* corresponding to 336.0 micrograms per mL A pre-filled syringe of 0.5 mL contains 20,000 international units (IU) corresponding to
168.0 micrograms epoetin alfa. *

Binocrit 30,000 IU/0.75 mL solution for injection in a pre-filled syringe
Each mL of solution contains 40,000 IU of epoetin alfa* corresponding to 336.0 micrograms per mL A pre-filled syringe of 0.75 mL contains 30,000 international units (IU) corresponding to
252.0 micrograms epoetin alfa. *

Binocrit 40,000 IU/1 mL solution for injection in a pre-filled syringe
Each mL of solution contains 40,000 IU of epoetin alfa* corresponding to 336.0 micrograms per mL A pre-filled syringe of 1 mL contains 40,000 international units (IU) corresponding to
336.0 micrograms epoetin alfa. *

* Produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology For the full list of excipients, see section 6.1.
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodium free”.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in a pre-filled syringe (injection) Clear, colourless solution


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Binocrit is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in adults and children aged 1 to 18 years on haemodialysis and adult patients on peritoneal dialysis (see section 4.4).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients (see section 4.4).</p><p>&nbsp;</p><p>Binocrit is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient&rsquo;s general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.</p><p>&nbsp;</p><p>Binocrit is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin [Hb] concentration range between 10 to 13 g/dl [6.2 to 8.1 mmol/l], no iron deficiency), if blood saving procedures are not&nbsp;available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).</p><p>&nbsp;</p><p>Binocrit is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. haemoglobin concentration range between 10 to 13 g/dl or 6.2 to 8.1 mmol/l) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1,800 mL).</p><p>&nbsp;</p><p>Binocrit is indicated for the treatment of symptomatic anaemia (haemoglobin concentration of &le; 10 g/dl) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (&lt; 200 mU/mL).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Binocrit has to be initiated under the supervision of physicians experienced in the management of patients with the above indications.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>All other causes of anaemia (iron, folate or vitamin B12 deficiency, aluminium intoxication, infection or inflammation, blood loss, haemolysis and bone marrow fibrosis of any origin) should be evaluated and treated prior to initiating therapy with epoetin alfa, and when deciding to increase the dose. In order to ensure optimum response to epoetin alfa, adequate iron stores should be assured and iron supplementation should be administered if necessary (see section 4.4).</p><p>&nbsp;</p><p><em><u>Treatment of symptomatic anaemia in adult chronic renal failure patients</u></em></p><p><em>&nbsp;</em></p><p>Anaemia symptoms and sequelae may vary with age, gender, and co-morbid medical conditions; a physician&rsquo;s evaluation of the individual patient&rsquo;s clinical course and condition is necessary.</p><p>&nbsp;</p><p>The recommended desired haemoglobin concentration range is between 10 g/dl to 12 g/dl (6.2 to 7.5 mmol/l). Binocrit should be administered in order to increase haemoglobin to not greater than 12 g/dl (7.5 mmol/l). A rise in haemoglobin of greater than 2 g/dl (1.25 mmol/l) over a four week period should be avoided. If it occurs, appropriate dose adjustment should be made as provided.</p><p>&nbsp;</p><p>Due to intra-patient variability, occasional individual haemoglobin values for a patient above and below the desired haemoglobin concentration range may be observed. Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin concentration range of 10 g/dl (6.2 mmol/l) to 12 g/dl (7.5 mmol/l).</p><p>&nbsp;</p><p>A sustained haemoglobin level of greater than 12 g/dl (7.5 mmol/l) should be avoided. If the haemoglobin is rising by more than 2 g/dl (1.25 mmol/l) per month, or if the sustained haemoglobin exceeds 12 g/dl (7.5 mmol/l) reduce the Binocrit dose by 25%. If the haemoglobin exceeds 13 g/dl (8.1 mmol/l), discontinue therapy until it falls below 12 g/dl (7.5 mmol/l) and then reinstitute Binocrit therapy at a dose 25% below the previous dose.</p><p>&nbsp;</p><p>Patients should be monitored closely to ensure that the lowest approved effective dose of Binocrit is used to provide adequate control of anaemia and of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dL (7.45 mmol/L).</p><p>&nbsp;</p><p>Caution should be exercised with escalation of Binocrit doses in patients with chronic renal failure. In patients with a poor haemoglobin response to Binocrit, alternative explanations for the poor response should be considered (see section 4.4 and 5.1).</p><p>&nbsp;</p><p>Treatment with Binocrit is divided into two stages &ndash; correction and maintenance phase.</p><p>&nbsp;</p><p><em><u>Adult haemodialysis patients</u></em></p><p><em>&nbsp;</em></p><p>In patients on haemodialysis where intravenous access is readily available, administration by the intravenous route is preferable.</p><p>&nbsp;</p><p><em>Correction phase</em></p><p>The starting dose is 50 IU/kg, 3 times per week.</p><p>&nbsp;</p><p>If necessary, increase or decrease the dose by 25 IU/kg (3 times per week) until the desired haemoglobin concentration range between 10 g/dl to 12 g/dl (6.2 to 7.5 mmol/l) is achieved (this should be done in steps of at least four weeks).</p><p>&nbsp;</p><p><em>Maintenance phase</em></p><p>The recommended total weekly dose is between 75 IU/kg and 300 IU/kg.</p><p>&nbsp;</p><p>Appropriate adjustment of the dose should be made in order to maintain haemoglobin values within the desired concentration range between 10 g/dl to 12 g/dl (6.2 to 7.5 mmol/l).</p><p>&nbsp;</p><p>Patients with very low initial haemoglobin (&lt; 6 g/dl or &lt; 3.75 mmol/l) may require higher maintenance doses than patients whose initial anaemia is less severe (&gt; 8 g/dl or &gt; 5 mmol/l).</p><p>&nbsp;</p><p><em><u>Adult patients with renal insufficiency not yet undergoing dialysis</u></em></p><p><em>&nbsp;</em></p><p>Where intravenous access is not readily available Binocrit may be administered subcutaneously.</p><p>&nbsp;</p><p><em>Correction phase</em></p><p>Starting dose of 50 IU/kg, 3 times per week, followed if necessary by a dosage increase with 25 IU/kg increments (3 times per week) until the desired goal is achieved (this should be done in steps of at least four weeks).</p><p>&nbsp;</p><p><em>Maintenance phase</em></p><p>During the maintenance phase, Binocrit can be administered either 3 times per week, and in the case of subcutaneous administration, once weekly or once every 2 weeks.</p><p>&nbsp;</p><p>Appropriate adjustment of dose and dose intervals should be made in order to maintain haemoglobin values at the desired level: haemoglobin between 10 g/dl and 12 g/dl (6.2 to 7.5 mmol/l). Extending dose intervals may require an increase in dose.</p><p>&nbsp;</p><p>The maximum dosage should not exceed 150 IU/kg, 3 times per week, 240 IU/kg (up to a maximum of 20,000 IU) once weekly, or 480 IU/kg (up to a maximum of 40,000 IU) once every 2 weeks.</p><p>&nbsp;</p><p><em><u>Adult peritoneal dialysis patients</u></em></p><p><em>&nbsp;</em></p><p>Where intravenous access is not readily available Binocrit may be administered subcutaneously.</p><p>&nbsp;</p><p><em>Correction phase</em></p><p>The starting dose is 50 IU/kg, 2 times per week.</p><p>&nbsp;</p><p><em>Maintenance phase</em></p><p>The recommended maintenance dose is between 25 IU/kg and 50 IU/kg, 2 times per week in 2 equal injections.</p><p>Appropriate adjustment of the dose should be made in order to maintain haemoglobin values at the desired level between 10 g/dl to 12 g/dl (6.2 to 7.5 mmol/l).</p><p>&nbsp;</p><p><em><u>Treatment of adult patients with chemotherapy-induced anaemia</u></em></p><p>Anaemia symptoms and sequelae may vary with age, gender, and overall burden of disease; a physician&rsquo;s evaluation of the individual patient&rsquo;s clinical course and condition is necessary.</p><p>&nbsp;</p><p>Binocrit should be administered to patients with anaemia (e.g. haemoglobin concentration &le; 10 g/dl (6.2 mmol/l)).</p><p>&nbsp;</p><p>The initial dose is 150 IU/kg subcutaneously, 3 times per week.</p><p>&nbsp;</p><p>Alternatively, Binocrit can be administered at an initial dose of 450 IU/kg subcutaneously once weekly.</p><p>&nbsp;</p><p>Appropriate adjustment of the dose should be made in order to maintain haemoglobin concentrations within the desired concentration range between 10 g/dl to 12 g/dl (6.2 to 7.5 mmol/l).</p><p>&nbsp;</p><p>Due to intra-patient variability, occasional individual haemoglobin concentrations for a patient above and below the desired haemoglobin concentration range may be observed. Haemoglobin variability should be addressed through dose management, with consideration for the desired haemoglobin concentration range between 10 g/dl (6.2 mmol/l) to 12 g/dl (7.5 mmol/l). A sustained haemoglobin concentration of greater than 12 g/dl (7.5 mmol/l) should be avoided; guidance for appropriate dose adjustment for when haemoglobin concentrations exceed 12 g/dl (7.5 mmol/l) is described below.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the haemoglobin concentration has increased by at least 1 g/dl (0.62 mmol/l) or the reticulocyte count has increased &sup3; 40,000 cells/&micro;l above baseline after 4 weeks of treatment, the dose should remain at 150 IU/kg 3 times per week or 450 IU/kg once weekly.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the haemoglobin concentration increase is &lt; 1 g/dl (&lt; 0.62 mmol/l) and the reticulocyte count has increased &lt; 40,000 cells/&micro;l above baseline, increase the dose to 300 IU/kg 3 times per week. If after an additional 4 weeks of therapy at 300 IU/kg 3 times per week, the haemoglobin concentration has increased &sup3; 1 g/dl (&sup3; 0.62 mmol/l) or the reticulocyte count has increased &sup3; 40,000 cells/&micro;l, the dose should remain at 300 IU/kg 3 times per week.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the haemoglobin concentration has increased &lt; 1 g/dl (&lt; 0.62 mmol/l) and the reticulocyte count has increased &lt; 40,000 cells/&micro;l above baseline, response is unlikely and treatment should be discontinued.</p><p>&nbsp;</p><p><em><u>Dose adjustment to maintain haemoglobin concentrations between 10 g/dl to 12 g/dl (6.2 to 7.5 mmol/l)</u></em></p><p><em>&nbsp;</em></p><p>If the haemoglobin concentration is increasing by more than 2 g/dl (1.25 mmol/l) per month, or if the haemoglobin concentration level exceeds 12 g/dl (7.5 mmol/l), reduce the Binocrit dose by about 25 to 50%.</p><p>&nbsp;</p><p>If the haemoglobin concentration level exceeds 13 g/dl (8.1 mmol/l), discontinue therapy until it falls below 12 g/dl (7.5 mmol/l) and then reinitiate Binocrit therapy at a dose 25% below the previous dose.</p><p>&nbsp;</p><p>The recommended dosing regimen is described in the following diagram:</p><p>&nbsp;</p><p>150 IU/kg 3x/week</p><p><!--[if gte vml 1]><v:group id="Group_x0020_29" o:spid="_x0000_s1048"
 style='position:absolute;left:0;text-align:left;margin-left:380.25pt;
 margin-top:37pt;width:39.4pt;height:22.1pt;z-index:251663360;
 mso-position-horizontal-relative:page' coordorigin="7605,740" coordsize="788,442"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:line id="Line_x0020_12" o:spid="_x0000_s1049" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="7613,750" to="8333,750"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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"/>
 <v:line id="Line_x0020_13" o:spid="_x0000_s1050" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="8333,750" to="8333,1082"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1pt"/>
 <v:shape id="Freeform_x0020_14" o:spid="_x0000_s1051" style='position:absolute;
  left:8273;top:1062;width:120;height:120;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m120,l,,60,120,120,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="120,1062;0,1062;60,1182;120,1062"
   o:connectangles="0,0,0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="53" height="30" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]><v:group
 id="Group_x0020_25" o:spid="_x0000_s1044" style='position:absolute;left:0;
 text-align:left;margin-left:197.55pt;margin-top:37.75pt;width:39.4pt;height:22.1pt;
 z-index:251664384;mso-position-horizontal-relative:page' coordorigin="3951,755"
 coordsize="788,442" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
">
 <v:line id="Line_x0020_16" o:spid="_x0000_s1045" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="4731,765" to="4731,765"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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"/>
 <v:line id="Line_x0020_17" o:spid="_x0000_s1046" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="4011,765" to="4011,1097"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1pt"/>
 <v:shape id="Freeform_x0020_18" o:spid="_x0000_s1047" style='position:absolute;
  left:3951;top:1077;width:120;height:120;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m120,l,,60,120,120,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="120,1077;0,1077;60,1197;120,1077"
   o:connectangles="0,0,0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="53" height="30" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image002.png" />or 450 IU/kg once weekly for 4 weeks</p><p>&nbsp;</p><p>&nbsp;</p><p>Reticulocyte count increase &sup3; 40,000/&micro;l&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reticulocyte count increase</p><p>&lt; 40,000/&micro;l</p><p><!--[if gte vml 1]><o:wrapblock><v:group id="Group_x0020_22"
  o:spid="_x0000_s1041" style='position:absolute;left:0;text-align:left;
  margin-left:197.25pt;margin-top:17.8pt;width:6pt;height:22.1pt;z-index:251660288;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="3945,356" coordsize="120,442"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_3" o:spid="_x0000_s1042" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4005,366" to="4005,698"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1pt"/>
  <v:shape id="Freeform_x0020_4" o:spid="_x0000_s1043" style='position:absolute;
   left:3945;top:678;width:120;height:120;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD0sRGGxgAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvQv/D8gpepG6UIhJdRUoDxVZpVGyPj+wzCc2+Ddltkv77riB4HGbmG2a57k0lWmpcaVnBZByB
IM6sLjlXcDomT3MQziNrrCyTgj9ysF49DJYYa9txSu3B5yJA2MWooPC+jqV0WUEG3djWxMG72Mag
D7LJpW6wC3BTyWkUzaTBksNCgTW9FJT9HH6Ngm2SnD8nu6r9sq/z928edenHvlNq+NhvFiA89f4e
vrXftILpM1y/hB8gV/8AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA9LERhsYAAADbAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" path="m120,l,,60,120,120,xe" fillcolor="black" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="120,678;0,678;60,798;120,678"
    o:connectangles="0,0,0,0"/>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><v:group id="Group_x0020_19" o:spid="_x0000_s1038" style='position:absolute;
  left:0;text-align:left;margin-left:413.45pt;margin-top:20.8pt;width:6pt;
  height:22.1pt;z-index:251661312;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  coordorigin="8269,416" coordsize="120,442" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
">
  <v:line id="Line_x0020_6" o:spid="_x0000_s1039" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="8329,426" to="8329,758"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1pt"/>
  <v:shape id="Freeform_x0020_7" o:spid="_x0000_s1040" style='position:absolute;
   left:8269;top:738;width:120;height:120;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m120,l,,60,120,120,xe" fillcolor="black" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="120,738;0,738;60,858;120,738"
    o:connectangles="0,0,0,0"/>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="9" height="31" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image003.png" /></td><td>&nbsp;</td><td style="vertical-align:top"><img width="9" height="31" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image004.png" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />or Hb increase &sup3; 1 g/dl&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and Hb increase &lt; 1 g/dl</p><p>&nbsp;</p><p>Target Hb&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 300 IU/kg</p><p>(&le; 12 g/dl)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3x/week</p><p><!--[if gte vml 1]><v:group id="Group_x0020_14" o:spid="_x0000_s1033"
 style='position:absolute;left:0;text-align:left;margin-left:344.35pt;
 margin-top:23.25pt;width:75pt;height:65.3pt;z-index:251665408;
 mso-position-horizontal-relative:page' coordorigin="6887,465" coordsize="1500,1306"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAK+ricsIFAACcFwAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWG1vo0YQ/l6p/2HFx1Y+sxgDts53
urPj6KT0err4fsAGsEHFu3TBjtOq/70z+2LAhVyavqiVkg9h8Q6zs88+M/PA67enfUGOqaxywRcO
feU6JOWxSHK+WzhfNutR5JCqZjxhheDpwnlIK+ftm2+/ec3mO8nKLI8JeODVnC2crK7L+XhcxVm6
Z9UrUaYc5rZC7lkNt3I3TiS7B8/7Yuy5bjDes5w7bxpXK1YzcpD5M1wVIv4pTZaMH1kFLot43v7F
xFjEf90zm/PjtSxvy08SI48/Hj9JkicLB5DjbA8QOWMzYczgdnzx1K5xcNrKPdqL7ZacFo4/CSee
P3XIw8KZTEPfp1PtLz3VJAaD2dSburBWDAaRN5tQ16yX/fgVD3F29agPCFIHA4NWgGqIEQ7sm/p2
49dSHEoC9xcA4MPKyw0cUqXhANyuLQgD6JC7+x9EAoCyQy0UTf52rIIoChXUfmBgbkCiUwsznbgB
7mkAoPjEb0sN0BKHl8SAEzTMuMl5Sjx7YB+PbXN8UuFDuFhmjO/S24yV6eahBASoWR5QOz+jUDvf
sXkFC38VsmjimQ2HF7wylKJ01t0rm5eyqq9TsSc4WDgFbEKdBjveVLWGxZooFMQ6LwpFgYKTewje
CwFJnKpEkSc4q27k7m5ZSHJkBSSP+jO77Jih6xWrMm2npjS/gGw8UctkKUuuzLhmeaHHgE/BcSHI
HAjUjHR5+XXmzq6iq8gf+V5wNfLd1Wr0br30R8GahtPVZLVcruhvGDP151meJCnHsG2po/4f6sg+
j6WoxLZ+FYv9GJI5j1Nb7qDYUbcpdtwCNO56VwSDYO1VBQ27wINVv8WWaJWhWw/XAsu1tUxTLL3E
U+RRlcraV5pp+uyAU/p3RajG5Cls8gLNJhpMzSq2TFGguapRONAL2eyND5pPeCKWQ1AgEnNIu8Rk
ywY8bPcFNJbvR8Ql0SQKSYQrqkNvzKg1+25MNi65J2ZJ9GldedZGucJwSRNzYzaxZuBKGWV9zqDg
teOCkHrjgrTXZhiX3x8XHFfL1WBcgPLZ1XBc0KpbzjDVe+OaWTOMK+qPC7pK2xcNw37AaBt8ZdWL
GO3iP3yU7QPYUG8guO4BDKKGhXcANuD6mXAs03UMUuTEDQlhRKAGY1dHmpaiwua8gd1C291MDKPB
CmcHjHUT3yi+wnqPG8OhoGfA02Tlo64p4KTMVRG3zvXV7ECmcU2wsjoEijb8lwtHOuRu4dzpBCpZ
jRtX24OhrtRgl2HF1tvei2O6Ecqixv2rpIZ1bUY38wVv24GXlpWds9dS+Qq0UVMe7LS9arPLJe1s
XIgq1VDhRlR9PO8IgWgVmU4/qZ7WdnTraJXqx5oJ9Xz3vTcbrYMoHPlrfzqahW40cuns/Sxw/Zm/
WnebiRICRjc/v5ngkaEcfHZv/XoLPbc/jNg2JntV7AGsKyN56pPWQfXpvUgekDZ3cIU+IoWmILxn
wCAT8heH3MPbw8Kpfj4wmTqk+MAr2Az1faBFrW78aQg0JLI9c9eeYTwGVwundiBVcbis4Q4eOZQy
32WwElXIcPEOBOQ2N1pFx4TRFVV9Wz8USCNIcfyX8uQTk+wzxFyo9E/56MutSUmwgM02mztU6W35
GdJM01DvXsGBriDdH1eFUNP1+4JWhZ7OyrbCM07+RVVIXc+od9vHAU5807AZb3u4FXwvmvB/oAlB
F2imNZpQdTDgl9V+mMTdt7PnasLzK9UsuKCSKuVIpqbmWzq1q/WfkITwXhEStaBK4UbHtVXJ0yQh
REvOETeO2noETXrVTVeOYDy9QbXVyBP1IKRjX1QdOYg2vWF15eAgVs+Rg27UG1dXDaJRb2AXanAw
MlQ5Z/32VDU4cJAdLdg5SajYL1LwH5aCIPZ0k7TyzV67Iq8pDHbeXrt2l95exCAHQfUiBv+jYhAr
DH7rBP148V1aKUrzHR0/frfv3/wOAAD//wMAUEsDBBQABgAIAAAAIQCRLWpJWAYAAA8aAAAaAAAA
Y2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWzsWUtvGzcQvhfof1jsvbHeio3Iga1H3MROgkhJkSOl
pXYZc5cLkrKjW5GceilQIC16aIDeeiiKBmiABr30xxhw0KY/okPuQ6RExQ+4QFDEAozd2W+Gw5nZ
b0jujZtPY+odYS4ISzp+9VrF93AyYQFJwo7/cDT47LrvCYmSAFGW4I4/x8K/uf3pJzfQ1oSSdMwQ
D0YRjrEHhhKxhTp+JGW6tbEhJiBG4hpLcQLPpozHSMItDzcCjo5hgJhu1CqV1kaMSOJvg0WpDPUp
/EukUIIJ5UNlBnsJimH0e9MpmWCNDQ6rCiHmoku5d4RoxwebATse4afS9ygSEh50/Ir+8ze2b2yg
rVyJyjW6ht5A/+V6uUJwWNNj8nBcDtpoNButndK+BlC5iuu3+61+q7SnAWgygZlmvpg2m7ubu71m
jjVA2aXDdq/dq1ctvGG/vuLzTlP9LLwGZfYbK/jBoAtRtPAalOGbK/hGo13rNiy8BmX41gq+Xdnp
NdoWXoMiSpLDFXSl2ap3i9mWkCmje074ZrMxaNdy4wsUVENZXWqIKUvkulqL0RPGBwBQQIokSTw5
T/EUTaAmu4iSMSfePgkjKLwUJUyAuFKrDCp1+K9+DX2lI4K2MDK0lV/giVgRKX88MeEklR3/Nlj1
Dcjpmzcnz16fPPv95Pnzk2e/5mNrU5beHkpCU+/dT9/88/JL7+/ffnz34tts6GW8MPFvf/nq7R9/
vs88zHgRitPvXr19/er0+6//+vmFw/oOR2MTPiIxFt5dfOw9YDFM0OE/HvOLaYwiREyNnSQUKEFq
FIf9vows9N05osiB28V2HB9xoBoX8NbsieXwMOIzSRwW70SxBTxgjO4y7ozCHTWWEebRLAndg/OZ
iXuA0JFr7C5KrCz3ZylwLHGZ7EbYcvM+RYlEIU6w9NQzdoixY3aPCbHiekAmnAk2ld5j4u0i4gzJ
iIytaloo7ZEY8jJ3OQj5tmJz8MjbZdQ16x4+spHwbiDqcH6EqRXGW2gmUewyOUIxNQO+j2TkcnI4
5xMT1xcSMh1iyrx+gIVw6dzjMF8j6XeAZtxpP6Dz2EZySQ5dNvcRYyayxw67EYpTF3ZIksjEfi4O
oUSRd59JF/yA2W+Iuoc8oGRtuh8RbKX7bDZ4CAxrurQoEPVkxh25vIWZVb/DOZ0irKkGGoDF6zFJ
ziT5JXpv/nf0DiR6+sNLx4yuhtLdhq18XJDMdzhxvk17SxS+DrdM3F3GA/Lh83YPzZL7GF6V1eb1
kbY/0rb/v6ftde/z1ZP1gp+ButWyNVuu68V7vHbtPiWUDuWc4n2hl+8CulIwAKHS03tUXO7l0ggu
1ZsMA1i4kCOt43EmvyAyGkYohTV+1VdGQpGbDoWXMgFLfy122lZ4OosPWJBtWatVtT3NyEMguZBX
mqUcthsyQ7fai21YaV57G+rtcuGA0r2IE8ZgthN1hxPtQqiCpDfnEDSHE3pmV+LFpsOL68p8kaoV
L8C1MiuwbPJgsdXxmw1QASXYVSGKA5WnLNVFdnUyrzLT64JpVQCsIYoKWGR6U/m6dnpqdlmpnSPT
lhNGudlO6MjoHiYiFOC8OpX0PG5cNNebi5Ra7qlQ6PGgtBZutK+/z4vL5hr0lrmBJiZT0MQ77vit
ehNKZoLSjj+FrT9cxinUjlDLXURDODSbSJ698JdhlpQL2UMiygKuSSdjg5hIzD1K4o6vpl+mgSaa
Q7Rv1RoQwgfr3CbQyofmHCTdTjKeTvFEmmk3JCrS2S0wfMYVzqda/fJgpclmkO5hFBx7YzrjDxCU
WLNdVQEMiIAToGoWzYDAkWZJZIv6W2pMOe2aZ4q6hjI5ommE8o5iknkG11ReuqPvyhgYd/mcIaBG
SPJGOA5VgzWDanXTsmtkPqztumcrqcgZpLnomRarqK7pZjFrhKINLMXyck3e8KoIMXCa2eEz6l6m
3M2C65bWCWWXgICX8XN03XM0BMO1xWCWa8rjVRpWnJ1L7d5RTPAM187TJAzWbxVml+JW9gjncCC8
VOcHveWqBdG0WFfqSLs+Txyg1BuH1Y4PnwjgbOIpXMFHBh9kNSWrKRlcwZcDaBfZcX/Hzy8KCTzP
JCWmXkjqBaZRSBqFpFlImoWkVUhavqfPxeFbjDoS973i2Bt6WH5Mnq8t7G842/8CAAD//wMAUEsD
BBQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdp
bmcxLnhtbC5yZWxzhI/NCsIwEITvgu8Q9m7SehCRJr2I0KvUBwjJNi02PyRR7Nsb6EVB8LIws+w3
s037sjN5YkyTdxxqWgFBp7yenOFw6y+7I5CUpdNy9g45LJigFdtNc8VZ5nKUxikkUigucRhzDifG
khrRykR9QFc2g49W5iKjYUGquzTI9lV1YPGTAeKLSTrNIXa6BtIvoST/Z/thmBSevXpYdPlHBMul
FxagjAYzB0pXZ501LV2BiYZ9/SbeAAAA//8DAFBLAQItABQABgAIAAAAIQC75UiUBQEAAB4CAAAT
AAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAK0wP/HB
AAAAMgEAAAsAAAAAAAAAAAAAAAAANgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhACvq4nLC
BQAAnBcAAB8AAAAAAAAAAAAAAAAAIAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWxQ
SwECLQAUAAYACAAAACEAkS1qSVgGAAAPGgAAGgAAAAAAAAAAAAAAAAAfCAAAY2xpcGJvYXJkL3Ro
ZW1lL3RoZW1lMS54bWxQSwECLQAUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAAAAAAAAAAAAAACv
DgAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsFBgAAAAAFAAUA
ZwEAALIPAAAAAA==
">
 <v:line id="Line_x0020_20" o:spid="_x0000_s1034" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="8327,475" to="8327,1671"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1pt"/>
 <v:shape id="Freeform_x0020_21" o:spid="_x0000_s1035" style='position:absolute;
  left:8267;top:1651;width:120;height:120;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m120,l,,60,120,120,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="120,1651;0,1651;60,1771;120,1651"
   o:connectangles="0,0,0,0"/>
 </v:shape><v:line id="Line_x0020_22" o:spid="_x0000_s1036" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="8327,1024" to="8327,1024"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1pt"/>
 <v:shape id="Freeform_x0020_23" o:spid="_x0000_s1037" style='position:absolute;
  left:6887;top:964;width:120;height:120;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m120,l,60r120,60l120,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="120,964;0,1024;120,1084;120,964"
   o:connectangles="0,0,0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="101" height="87" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image005.png" /><!--[if gte vml 1]><v:group
 id="Group_x0020_11" o:spid="_x0000_s1030" style='position:absolute;left:0;
 text-align:left;margin-left:197.5pt;margin-top:8.85pt;width:6pt;height:22.1pt;
 z-index:251666432;mso-position-horizontal-relative:page' coordorigin="3950,177"
 coordsize="120,442" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
">
 <v:line id="Line_x0020_25" o:spid="_x0000_s1031" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="4010,609" to="4010,609"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1pt"/>
 <v:shape id="Freeform_x0020_26" o:spid="_x0000_s1032" style='position:absolute;
  left:3950;top:177;width:120;height:120;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m60,l,120r120,l60,xe" fillcolor="black" stroked="f">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="60,177;0,297;120,297;60,177"
   o:connectangles="0,0,0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="8" height="30" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image006.png" />for 4 weeks</p><p>&nbsp;</p><p>&nbsp;</p><p>Reticulocyte count increase &sup3; 40,000/&micro;l or Hb increase &sup3; 1 g/dl</p><p>&nbsp;</p><p>&nbsp;</p><p>Reticulocyte count increase</p><p>&lt; 40,000/&micro;l</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_8" o:spid="_x0000_s1027" style='position:absolute;left:0;
  text-align:left;margin-left:413.9pt;margin-top:19pt;width:6pt;height:22.1pt;
  z-index:251662336;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="8278,380" coordsize="120,442"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
">
  <v:line id="Line_x0020_9" o:spid="_x0000_s1028" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="8338,390" to="8338,722"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1pt"/>
  <v:shape id="Freeform_x0020_10" o:spid="_x0000_s1029" style='position:absolute;
   left:8278;top:702;width:120;height:120;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="120,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m120,l,,60,120,120,xe" fillcolor="black" stroked="f">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="120,702;0,702;60,822;120,702"
    o:connectangles="0,0,0,0"/>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="9" height="30" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image007.png" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />and Hb increase &lt; 1 g/dl</p><p>&nbsp;</p><p>Discontinue therapy</p><p>&nbsp;</p><p>Patients should be monitored closely to ensure that the lowest approved dose of erythropoiesis- stimulating agent (ESA) is used to provide adequate control of the symptoms of anaemia.</p><p>&nbsp;</p><p>Epoetin alfa therapy should continue until one month after the end of chemotherapy.</p><p>&nbsp;</p><p><em><u>Treatment of adult surgery patients in an autologous predonation programme</u></em></p><p>Mildly anaemic patients (haematocrit of 33 to 39%) requiring predeposit of &sup3; 4 units of blood should be treated with Binocrit 600 IU/kg intravenously, 2 times per week for 3 weeks prior to surgery.</p><p>Binocrit should be administered after the completion of the blood donation procedure.</p><p>&nbsp;</p><p><em><u>Treatment of adult patients scheduled for major elective orthopaedic surgery</u></em></p><p><em>&nbsp;</em></p><p>The recommended dose is Binocrit 600 IU/kg, administered subcutaneously weekly for three weeks (days -21, -14 and -7) prior to surgery and on the day of surgery (day 0).</p><p>&nbsp;</p><p>In cases where there is a medical need to shorten the lead time before surgery to less than three weeks, Binocrit 300 IU/kg should be administered subcutaneously daily for 10 consecutive days prior to surgery, on the day of surgery and for four days immediately thereafter.</p><p>&nbsp;</p><p>If the haemoglobin level reaches 15 g/dl (9.38 mmol/l), or higher, during the preoperative period, administration of Binocrit should be stopped and further dosages should not be administered.</p><p>&nbsp;</p><p><em><u>Treatment of adult patients with low- or intermediate-1-risk MDS</u></em></p><p><em>&nbsp;</em></p><p>Binocrit should be administered to patients with symptomatic anaemia (e.g. haemoglobin concentration &le; 10 g/dl (6.2 mmol/l)).</p><p>&nbsp;</p><p>The recommended starting dose is Binocrit 450 IU/kg (maximum total dose is 40,000 IU) administered subcutaneously once every week, with not less than 5 days between doses.</p><p>&nbsp;</p><p>Appropriate dose adjustments should be made to maintain haemoglobin concentrations within the target range of 10 g/dl to 12 g/dl (6.2 to 7.5 mmol/l). It is recommended that initial erythroid response be assessed 8 to 12 weeks following initiation of treatment. Dose increases and decreases should be done one dosing step at a time (see diagram below). A haemoglobin concentration of greater than</p><p>12 g/dl (7.5 mmol/l) should be avoided.</p><p>&nbsp;</p><p>Dose increase: Dose should not be increased over the maximum of 1050 IU/kg (total dose 80,000 IU) per week. If the patient loses response or haemoglobin concentration drops by &ge; 1 g/dl upon dose reduction the dose should be increased by one dosing step. A minimum of 4 weeks should elapse between dose increases.</p><p>&nbsp;</p><p>Dose hold and decrease: Epoetin alfa should be withheld when the haemoglobin concentration exceeds 12 g/dl (7.5 mmol/l). Once the haemoglobin level is &lt; 11 g/dl the dose can be restarted on the same dosing step or one dosing step down based on physician judgement. Decreasing the dose by one dosing step should be considered if there is a rapid increase in haemoglobin (&gt; 2 g/dl over 4 weeks).</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image1.jpeg" o:spid="_x0000_s1026" type="#_x0000_t75"
  style='position:absolute;margin-left:70.9pt;margin-top:11.3pt;width:408.05pt;
  height:174.85pt;z-index:251659264;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image008.jpg"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="544" height="233" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image009.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>Anaemia symptoms and sequelae may vary with age, gender, and co-morbid medical conditions; a physician&#39;s evaluation of the individual patient&#39;s clinical course and condition is necessary.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p><em>&nbsp;</em></p><p><em><u>Treatment of symptomatic anaemia in chronic renal failure patients on haemodialysis</u></em></p><p>Anaemia symptoms and sequelae may vary with age, gender, and co-morbid medical conditions; a physician&rsquo;s evaluation of the individual patient&rsquo;s clinical course and condition is necessary.</p><p>&nbsp;</p><p>In paediatric patients the recommended haemoglobin concentration range is between 9.5 g/dl to 11 g/dl (5.9 to 6.8 mmol/l). Binocrit should be administered in order to increase haemoglobin to not greater than 11 g/dl (6.8 mmol/l). A rise in haemoglobin of greater than 2 g/dl (1.25 mmol/l) over a four week period should be avoided. If it occurs, appropriate dose adjustment should be made as provided.</p><p>&nbsp;</p><p>Patients should be monitored closely to ensure that the lowest approved dose of Binocrit is used to provide adequate control of anaemia and of the symptoms of anaemia.</p><p>&nbsp;</p><p>Treatment with Binocrit is divided into two stages &ndash; correction and maintenance phase.</p><p>&nbsp;</p><p>In paediatric patients on haemodialysis where intravenous access is readily available, administration by the intravenous route is preferable.</p><p>&nbsp;</p><p><em>Correction phase</em></p><p>The starting dose is 50 IU/kg intravenously, 3 times per week.</p><p>&nbsp;</p><p>If necessary, increase or decrease the dose by 25 IU/kg (3 times per week) until the desired haemoglobin concentration range of between 9.5 g/dl to 11 g/dl (5.9 to 6.8 mmol/l) is achieved (this should be done in steps of at least four weeks).</p><p>&nbsp;</p><p><em>Maintenance phase</em></p><p>Appropriate adjustment of the dose should be made in order to maintain haemoglobin levels within the desired concentration range between 9.5 g/dl to 11 g/dl (5.9 to 6.8 mmol/l).</p><p>&nbsp;</p><p>Generally, children under 30 kg require higher maintenance doses than children over 30 kg and adults. Paediatric patients with very low initial haemoglobin (&lt; 6.8 g/dl or &lt; 4.25 mmol/l) may require higher maintenance doses than patients whose initial haemoglobin is higher (&gt; 6.8 g/dl or &gt; 4.25 mmol/l).</p><p>&nbsp;</p><p><em><u>Anaemia in chronic renal failure patients before initiation of dialysis or on peritoneal dialysis</u></em></p><p>The safety and efficacy of epoetin alfa in chronic renal failure patients with anaemia before initiation of dialysis or on peritoneal dialysis have not been established. Currently available data for subcutaneous use of epoetin alfa in these populations are described in section 5.1 but no recommendation on posology can be made.</p><p>&nbsp;</p><p><em><u>Treatment of paediatric patients with chemotherapy-induced anaemia</u></em></p><p>The safety and efficacy of epoetin alfa in paediatric patients receiving chemotherapy have not been established (see section 5.1).</p><p>&nbsp;</p><p><em><u>Treatment of paediatric surgery patients in an autologous predonation programme</u></em></p><p>The safety and efficacy of epoetin alfa in paediatrics have not been established. No data are available.</p><p>&nbsp;</p><p><em><u>Treatment of paediatric patients scheduled for major elective orthopaedic surgery</u></em></p><p>The safety and efficacy of epoetin alfa in paediatrics have not been established. No data are available. <u>Method of administration</u></p><p>Precautions to be taken before handling or administering the medicinal product.</p><p>&nbsp;</p><p>Before use, leave the Binocrit syringe to stand until it reaches room temperature. This usually takes between 15 and 30 minutes.</p><p>As with any other injectable product, check that there are no particles in the solution or change in colour. Binocrit is a sterile but unpreserved product and is for single use only. Administer the amount required.</p><p>&nbsp;</p><p><em><u>Treatment of symptomatic anaemia in adult chronic renal failure patients</u></em></p><p><em>&nbsp;</em></p><p>In patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Binocrit by the intravenous route is preferable.</p><p>&nbsp;</p><p>Where intravenous access is not readily available (patients not yet undergoing dialysis and peritoneal dialysis patients) Binocrit may be administered as a subcutaneous injection.</p><p>&nbsp;</p><p><em><u>Treatment of adult patients with chemotherapy-induced anaemia</u></em></p><p>Binocrit should be administered as a subcutaneous injection.</p><p>&nbsp;</p><p><em><u>Treatment of adult surgery patients in an autologous predonation programme</u></em></p><p>Binocrit should be administered by the intravenous route.</p><p>&nbsp;</p><p><em><u>Treatment of adult patients scheduled for major elective orthopaedic surgery</u></em></p><p>Binocrit should be administered as a subcutaneous injection.</p><p>&nbsp;</p><p><em><u>Treatment of adult patients with low- or intermediate-1-risk MDS</u></em></p><p>Binocrit should be administered as a subcutaneous injection.</p><p>&nbsp;</p><p><em><u>Treatment of symptomatic anaemia in paediatric chronic renal failure patients on haemodialysis</u></em></p><p>&nbsp;</p><p>In paediatric patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Binocrit by the intravenous route is preferable.</p><p>&nbsp;</p><p><em><u>Intravenous administration</u></em></p><p>Administer over at least one to five minutes, depending on the total dose. In haemodialysed patients, a bolus injection may be given during the dialysis session through a suitable venous port in the dialysis line. Alternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10 mL of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation (see Posology, &ldquo;Adult haemodialysis patients&rdquo;).</p><p>&nbsp;</p><p>A slower administration is preferable in patients who react to the treatment with &ldquo;flu-like&rdquo; symptoms (see section 4.8).</p><p>&nbsp;</p><p>Do not administer Binocrit by intravenous infusion or in conjunction with other medicinal product solutions (please refer to section 6.6 for further information).</p><p>&nbsp;</p><p><em><u>Subcutaneous administration</u></em></p><p>A maximum volume of 1 mL at one injection site should generally not be exceeded. In case of larger volumes, more than one site should be chosen for the injection.</p><p>&nbsp;</p><p>The injections should be given in the limbs or the anterior abdominal wall.</p><p>&nbsp;</p><p>In those situations in which the physician determines that a patient or caregiver can safely and effectively administer Binocrit subcutaneously themselves, instruction as to the proper dosage and administration should be provided.</p><p>Graduation rings</p><p>The syringe contains graduation rings to provide for the administration of a part of the dose (see section&nbsp;6.6). However the product is for single use only. Only one dose of Binocrit from each syringe should be taken.</p><p>&nbsp;</p><p>&ldquo;Instructions on how to inject Binocrit yourself&rdquo; can be found at the end of the package leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

-	Patients who develop pure red cell aplasia (PRCA) following treatment with any erythropoietin should not receive Binocrit or any other erythropoietin (see section 4.4).

-	Uncontrolled hypertension.

-	All contraindications associated with autologous blood predonation programmes should be respected in patients being supplemented with Binocrit.

The use of Binocrit in patients scheduled for major elective orthopaedic surgery and not participating in an autologous blood predonation programme is contraindicated in patients with severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.

-	Surgery patients who for any reason cannot receive adequate antithrombotic prophylaxis.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>&nbsp;</p><p>In all patients receiving epoetin alfa, blood pressure should be closely monitored and controlled as necessary. Epoetin alfa should be used with caution in the presence of untreated, inadequately treated or poorly controllable hypertension. It may be necessary to add or increase anti-hypertensive treatment. If blood pressure cannot be controlled, epoetin alfa treatment should be discontinued.</p><p>&nbsp;</p><p>Hypertensive crisis with encephalopathy and seizures, requiring the immediate attention of a physician and intensive medical care, have occurred also during epoetin alfa treatment in patients with&nbsp; &nbsp;previously normal or low blood pressure. Particular attention should be paid to sudden stabbing migraine-like headaches as a possible warning signal (see section 4.8).</p><p>&nbsp;</p><p>Epoetin alfa should be used with caution in patients with epilepsy, history of seizures, or medical conditions associated with a predisposition to seizure activity such as CNS infections and brain metastases.</p><p>&nbsp;</p><p>Epoetin alfa should be used with caution in patients with chronic liver failure. The safety of epoetin alfa has not been established in patients with hepatic dysfunction.</p><p>&nbsp;</p><p>An increased incidence of thrombotic vascular events (TVEs) has been observed in patients receiving ESAs (see section 4.8). These include venous and arterial thromboses and embolism (including some with fatal outcomes), such as deep venous thrombosis, pulmonary emboli, retinal thrombosis, and myocardial infarction. Additionally, cerebrovascular accidents (including cerebral infarction, cerebral haemorrhage and transient ischaemic attacks) have been reported.</p><p>&nbsp;</p><p>The reported risk of these TVEs should be carefully weighed against the benefits to be derived from treatment with epoetin alfa particularly in patients with pre-existing risk factors for TVE, including obesity and prior history of TVEs (e.g. deep venous thrombosis, pulmonary embolism, and cerebral vascular accident).</p><p>&nbsp;</p><p>In all patients, haemoglobin levels should be closely monitored due to a potential increased risk of thromboembolic events and fatal outcomes when patients are treated at haemoglobin levels above the concentration range for the indication of use.</p><p>&nbsp;</p><p>There may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with epoetin alfa. This regresses during the course of continued therapy. In addition, thrombocythaemia above the normal range has been reported. It is recommended that the platelet count is regularly monitored during the first 8 weeks of therapy.</p><p>&nbsp;</p><p>All other causes of anaemia (iron, folate or vitamin B12 deficiency, aluminium intoxication, infection or inflammation, blood loss, haemolysis and bone marrow fibrosis of any origin) should be evaluated and treated prior to initiating therapy with epoetin alfa, and when deciding to increase the dose. In most cases, the ferritin values in the serum fall simultaneously with the rise in packed cell volume. In order to ensure optimum response to epoetin alfa, adequate iron stores should be assured and iron supplementation should be administered if necessary (see section 4.2):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For chronic renal failure patients, iron supplementation (elemental iron 200 to 300 mg/day orally for adults and 100 to 200 mg/day orally for paediatrics) is recommended if serum ferritin levels are below 100 ng/mL.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For cancer patients, iron supplementation (elemental iron 200 to 300 mg/day orally) is recommended if transferrin saturation is below 20%.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients in an autologous predonation programme, iron supplementation (elemental iron 200 mg/day orally) should be administered several weeks prior to initiating the autologous predeposit in order to achieve high iron stores prior to starting epoetin alfa therapy, and throughout the course of epoetin alfa therapy.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients scheduled for major elective orthopaedic surgery, iron supplementation (elemental iron 200 mg/day orally) should be administered throughout the course of epoetin alfa therapy. If possible, iron supplementation should be initiated prior to starting epoetin alfa therapy to achieve adequate iron stores.</p><p>&nbsp;</p><p>Very rarely, development of or exacerbation of porphyria has been observed in epoetin alfa-treated patients. Epoetin alfa should be used with caution in patients with porphyria.</p><p>&nbsp;</p><p>Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in association with epoetin treatment. More severe cases have been observed with long-acting epoetins.</p><p>&nbsp;</p><p>At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, Binocrit should be withdrawn immediately and an alternative treatment considered.</p><p>&nbsp;</p><p>If the patient has developed a severe cutaneous skin reaction such as SJS or TEN due to the use of Binocrit, treatment with Binocrit must not be restarted in this patient at any time.</p><p>&nbsp;</p><p>In order to improve the traceability of erythropoiesis-stimulating agents (ESAs), the trade name and the batch number of the administered ESA should be clearly recorded (or stated) in the patient file.</p><p>Patients should only be switched from one ESA to another under appropriate supervision. <u>Pure Red Cell Aplasia (PRCA)</u></p><p>Antibody-mediated PRCA has been reported after months to years of epoetin alfa treatment Cases have also been reported in patients with hepatitis C treated with interferon and ribavirin, when ESAs are used concomitantly. Epoetin alfa is not approved in the management of anaemia associated with hepatitis C.</p><p>&nbsp;</p><p>In patients developing sudden lack of efficacy defined by a decrease in haemoglobin (1 to 2 g/dl or</p><p>0.62 to 1.25 mmol/l per month) with increased need for transfusions, a reticulocyte count should be obtained and typical causes of non-response (e.g. iron, folate or vitamin B12 deficiency, aluminium intoxication, infection or inflammation, blood loss, haemolysis and bone marrow fibrosis of any origin) should be investigated.</p><p>&nbsp;</p><p>A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin alfa and perform anti- erythropoietin antibody testing. A bone marrow examination should also be considered for diagnosis of PRCA.</p><p>&nbsp;</p><p>No other ESA therapy should be commenced because of the risk of cross-reaction.</p><p>&nbsp;</p><p><u>Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patients</u></p><p>&nbsp;</p><p>Chronic renal failure patients being treated with epoetin alfa should have haemoglobin levels measured on a regular basis until a stable level is achieved, and periodically thereafter.</p><p>&nbsp;</p><p>In chronic renal failure patients the rate of increase in haemoglobin should be approximately 1 g/dl (0.62 mmol/l) per month and should not exceed 2 g/dl (1.25 mmol/l) per month to minimise risks of an increase in hypertension.</p><p>In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the haemoglobin concentration range as recommended in section 4.2. In clinical trials, an increased risk of death and serious cardiovascular events was observed when ESAs were administered to achieve a haemoglobin concentration level of greater than 12 g/dl (7.5 mmol/l).</p><p>&nbsp;</p><p>Controlled clinical trials have not shown significant benefits attributable to the administration of epoetins when haemoglobin concentration is increased beyond the level necessary to control symptoms of anaemia and to avoid blood transfusion.</p><p>&nbsp;</p><p>Caution should be exercised with escalation of Binocrit doses in patients with chronic renal failure since high cumulative epoetin doses may be associated with an increased risk of mortality, serious cardiovascular and cerebrovascular events. In patients with a poor haemoglobin response to epoetins, alternative explanations for the poor response should be considered (see section 4.2 and 5.1).</p><p>&nbsp;</p><p>Chronic renal failure patients treated with epoetin alfa by the subcutaneous route should be monitored regularly for loss of efficacy, defined as absent or decreased response to epoetin alfa treatment patients who previously responded to such therapy. This is characterised by a sustained decrease in haemoglobin despite an increase in epoetin alfa dosage (see section 4.8).</p><p>&nbsp;</p><p>Some patients with more extended dosing intervals (greater than once weekly) of epoetin alfa may not maintain adequate haemoglobin levels (see section 5.1) and may require an increase in epoetin alfa dose. Haemoglobin levels should be monitored regularly.</p><p>&nbsp;</p><p>Shunt thromboses have occurred in haemodialysis patients, especially in those who have a tendency to hypotension or whose arteriovenous fistulae exhibit complications (e.g. stenoses, aneurysms, etc.).</p><p>Early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid, for example, is recommended in these patients.</p><p>Hyperkalaemia has been observed in isolated cases though causality has not been established. Serum electrolytes should be monitored in chronic renal failure patients. If an elevated or rising serum potassium level is detected, then in addition to appropriate treatment of the hyperkalaemia, consideration should be given to ceasing epoetin alfa administration until the serum potassium level has been corrected.</p><p>&nbsp;</p><p>An increase in heparin dose during haemodialysis is frequently required during the course of therapy with epoetin alfa as a result of the increased packed cell volume. Occlusion of the dialysis system is possible if heparinisation is not optimum.</p><p>&nbsp;</p><p>Based on information available to date, correction of anaemia with epoetin alfa in adult patients with renal insufficiency not yet undergoing dialysis does not accelerate the rate of progression of renal insufficiency.</p><p>&nbsp;</p><p><u>Treatment of patients with chemotherapy-induced anaemia</u></p><p>&nbsp;</p><p>Cancer patients being treated with epoetin alfa should have haemoglobin levels measured on a regular basis until a stable level is achieved, and periodically thereafter.</p><p>&nbsp;</p><p>Epoetins are growth factors that primarily stimulate red blood cell production. Erythropoietin receptors may be expressed on the surface of a variety of tumour cells. As with all growth factors, there is a concern that epoetins could stimulate the growth of tumours. The role of ESAs on tumour progression or reduced progression-free survival cannot be excluded. In controlled clinical studies, use of epoetin alfa and other ESAs have been associated with decreased locoregional tumour control or decreased overall survival:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased locoregional control in patients with advanced head and neck cancer receiving radiation therapy when administered to achieve a haemoglobin concentration level of greater than 14 g/dl (8.7 mmol/l),</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to achieve a haemoglobin concentration range of 12 to 14 g/dl (7.5 to 8.7 mmol/l),</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased risk of death when administered to achieve a haemoglobin concentration level of 12 g/dl (7.5 mmol/l) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy. ESAs are not indicated for use in this patient population,</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an observed 9% increase in risk for progress of disease (PD) or death in the epoetin alfa plus SOC group from a primary analysis and a 15% increased risk that cannot be statistically ruled out in patients with metastatic breast cancer receiving chemotherapy when administered to achieve a haemoglobin concentration range of 10 to 12 g/dl (6.2 to 7.5 mmol/l).</p><p>&nbsp;</p><p>In view of the above, in some clinical situations blood transfusion should be the preferred treatment for the management of anaemia in patients with cancer. The decision to administer recombinant erythropoietin treatment should be based on a benefit-risk assessment with the participation of the individual patient, which should take into account the specific clinical context. Factors that should be considered in this assessment should include the type of tumour and its stage; the degree of anaemia;</p><p>&nbsp;</p><p>life-expectancy; the environment in which the patient is being treated; and patient preference (see section 5.1).</p><p>&nbsp;</p><p>In cancer patients receiving chemotherapy, the 2 to 3 week delay between ESA administration and the appearance of erythropoietin-induced red cells should be taken into account when assessing if epoetin alfa therapy is appropriate (patient at risk of being transfused).</p><p>&nbsp;</p><p><u>Surgery patients in autologous predonation programmes</u></p><p>&nbsp;</p><p>All special warnings and special precautions associated with autologous predonation programmes, especially routine volume replacement, should be respected.</p><p>&nbsp;</p><p><u>Patients scheduled for major elective orthopaedic surgery</u></p><p>&nbsp;</p><p>Good blood management practices should always be used in the perisurgical setting.</p><p>&nbsp;</p><p>Patients scheduled for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis, as thrombotic and vascular events may occur in surgical patients, especially in those with underlying cardiovascular disease. In addition, special precaution should be taken in patients with predisposition for development of DVTs. Moreover, in patients with a baseline haemoglobin of &gt; 13 g/dl (&gt; 8.1 mmol/l), the possibility that epoetin alfa treatment may be associated with an increased risk of postoperative thrombotic/vascular events cannot be excluded. Therefore, epoetin alfa should not be used in patients with baseline haemoglobin &gt; 13 g/dl (&gt; 8.1 mmol/l).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p>This medicine contains less than 1 mmol sodium (23 mg) per pre-filled syringe, that is to say essentially &ldquo;sodium-free&rdquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No evidence exists that indicates that treatment with epoetin alfa alters the metabolism of other medicinal products.</p><p>Medicinal products that decrease erythropoiesis may decrease the response to epoetin alfa.</p><p>&nbsp;</p><p>Since cyclosporin is bound by red blood cells (RBCs) there is potential for a medicinal product interaction. If epoetin alfa is given concomitantly with cyclosporin, blood levels of cyclosporin should be monitored and the dose of cyclosporin adjusted as the haematocrit rises.</p><p>&nbsp;</p><p>No evidence exists that indicates an interaction between epoetin alfa and granulocyte colony- stimulating factor (G-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF) with regard to haematological differentiation or proliferation of tumour biopsy specimens <em>in vitro</em>.</p><p>&nbsp;</p><p>In female adult patients with metastatic breast cancer, subcutaneous co-administration of 40,000 IU/mL epoetin alfa with trastuzumab 6 mg/kg had no effect on the pharmacokinetics of trastuzumab.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data from the use of epoetin alfa in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Consequently, epoetin alfa should be used in pregnancy only if the potential benefit outweighs the potential risk to the foetus. The use of epoetin alfa is not recommended in pregnant surgical patients participating in an autologous blood predonation programme.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether exogenous epoetin alfa is excreted in human milk. Epoetin alfa should be used with caution in nursing women. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy with epoetin alfa taking into account the benefit of breast-feeding for the child and the benefit of epoetin alfa therapy for the woman.</p><p>&nbsp;</p><p>The use of epoetin alfa is not recommended in lactating surgical patients participating in an autologous blood predonation programme.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no studies assessing the potential effect of epoetin alfa on male or female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Binocrit has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Summary of the safety profile</u></em></p><p>The most frequent adverse drug reaction during treatment with epoetin alfa is a dose-dependent increase in blood pressure or aggravation of existing hypertension. Monitoring of the blood pressure should be performed, particularly at the start of therapy (see section 4.4).</p><p>&nbsp;</p><p>The most frequently occurring adverse drug reactions observed in clinical trials of epoetin alfa are diarrhoea, nausea, vomiting, pyrexia and headache. Influenza-like illness may occur especially at the start of treatment.</p><p>&nbsp;</p><p>Respiratory tract congestion, which includes events of upper respiratory tract congestion, nasal congestion and nasopharyngitis, have been reported in studies with extended interval dosing in adult patients with renal insufficiency not yet undergoing dialysis.</p><p>&nbsp;</p><p>An increased incidence of thrombotic vascular events (TVEs) has been observed in patients receiving ESAs (see section 4.4).</p><p>&nbsp;</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p>Of a total 3,417 subjects in 25 randomised, double-blinded, placebo or standard of care controlled studies, the overall safety profile of epoetin alfa was evaluated in 2,094 anaemic subjects. Included were 228 epoetin alfa-treated CRF subjects in 4 chronic renal failure studies (2 studies in pre-dialysis [N = 131 exposed CRF subjects] and 2 in dialysis [N = 97 exposed CRF subjects]; 1,404 exposed cancer subjects in 16 studies of anaemia due to chemotherapy; 147 exposed subjects in 2 studies for autologous blood donation; 213 exposed subjects in 1 study in the perisurgical period, and</p><p>102 exposed subjects in 2 MDS studies. Adverse drug reactions reported by &ge; 1% of subjects treated with epoetin alfa in these trials are shown in the table below.</p><p>&nbsp;</p><p>Frequency estimate: Very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100&nbsp;to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000&nbsp;to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Classification (SOC)</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reaction (Preferred Term Level)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Pure red cell aplasia3, &nbsp;Thrombocythaemia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Hyperkalaemia1</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity3</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction3</p></td><td style="vertical-align:top"><p>Rare</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Convulsion</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypertension, Venous and arterial thromboses2</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypertensive crisis3</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory tract congestion</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea, Nausea, Vomiting</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria3</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Angioneurotic oedema3</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia, Bone pain, Myalgia, Pain in extremity</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Congenital, familial and genetic disorders</p></td><td style="vertical-align:top"><p>Porphyria acute3</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Chills, Influenza like illness, Injection site reaction, Oedema peripheral</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Medicinal product ineffective3</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Anti-erythropoietin antibody positive</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>1 Common in dialysis</p><p>2 Includes arterial and venous, fatal and non fatal events, such as deep venous thrombosis, pulmonary emboli, retinal thrombosis, arterial thrombosis (including myocardial infarction), cerebrovascular accidents (including cerebral infarction and cerebral haemorrhage) transient ischaemic attacks, and shunt thrombosis (including dialysis equipment) and thrombosis within arteriovenous shunt aneurisms 3 Addressed in the subsection below and/or in section 4.4</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Description of selected adverse reactions</u></em></p><p><em>&nbsp;</em></p><p>Hypersensitivity reactions, including cases of rash (including urticaria), anaphylactic reactions, and angioneurotic oedema have been reported (see section 4.4).</p><p>&nbsp;</p><p>Hypertensive crisis with encephalopathy and seizures, requiring the immediate attention of a physician and intensive medical care, have occurred also during epoetin alfa treatment in patients with previously normal or low blood pressure. Particular attention should be paid to sudden stabbing migraine-like headaches as a possible warning signal (see section 4.4).</p><p>&nbsp;</p><p>Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in association with epoetin treatment (see section 4.4).</p><p>&nbsp;</p><p>Antibody-mediated pure red cell aplasia has been very rarely reported in &lt; 1/10,000 cases per patient year after months to years of treatment with epoetin alfa (see section 4.4). More cases have been reported with subcutaneous (SC) route of administration, compared with the IV route.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Adult patients with low- or intermediate-1-risk MDS</u></em></p><p>In the randomised, double-blind, placebo-controlled, multicentre study 4 (4.7%) subjects experienced TVEs (sudden death, ischaemic stroke, embolism, and phlebitis). All TVEs occurred in the epoetin alfa group and in the first 24 weeks of the study. Three were confirmed TVE and in the remaining case (sudden death), the thromboembolic event was not confirmed. Two subjects had significant risk factors (atrial fibrillation, heart failure and thrombophlebitis).</p><p>&nbsp;</p><p><em><u>Paediatric population with chronic renal failure on haemodialysis</u></em></p><p>The exposure of paediatric patients with chronic renal failure on haemodialysis in clinical trials and post-marketing experience is limited. No paediatric-specific adverse reactions not mentioned previously in the table above, or any that were not consistent with the underlying disease were reported in this population.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The therapeutic margin of epoetin alfa is very wide. Overdosage of epoetin alfa may produce effects that are extensions of the pharmacological effects of the hormone. Phlebotomy may be performed if excessively high haemoglobin levels occur. Additional supportive care should be provided as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antianaemic preparations, erythropoietin, ATC code: B03XA01.</p><p>&nbsp;</p><p>Binocrit is a biosimilar medicinal product. Detailed information is available on the website of the European Medicines Agency http://www.ema.europa.eu.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Erythropoietin (EPO) is a glycoprotein hormone produced primarily by the kidney in response to hypoxia and is the key regulator of red blood cell (RBC) production. EPO is involved in all phases of erythroid development, and has its principal effect at the level of erythroid precursors. After EPO binds to its cell surface receptor, it activates signal transduction pathways that interfere with apoptosis and stimulates erythroid cell proliferation.</p><p>Recombinant human EPO (epoetin alfa), expressed in Chinese hamster ovary cells, has a 165 amino acid sequence identical to that of human urinary EPO; the 2 are indistinguishable on the basis of functional assays. The apparent molecular weight of erythropoietin is 32,000 to 40,000 dalton.</p><p>&nbsp;</p><p>Erythropoietin is a growth factor that primarily stimulates red cell production. Erythropoietin receptors may be expressed on the surface of a variety of tumour cells.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><em><u>Healthy volunteers</u></em></p><p>After single doses (20,000 to 160,000 IU subcutaneously) of epoetin alfa, a dose-dependent response was observed for the pharmacodynamic markers investigated including: reticulocytes, RBCs, and haemoglobin. A defined concentration-time profile with peak and return to baseline was observed for changes in percent reticulocytes. A less defined profile was observed for RBCs and haemoglobin. In general, all pharmacodynamic markers increased in a linear manner with dose reaching a maximum response at the highest dose levels.</p><p>&nbsp;</p><p>Further pharmacodynamic studies explored 40,000 IU once weekly versus 150 IU/kg 3 times per week. Despite differences in concentration-time profiles the pharmacodynamic response (as measured by changes in percent reticulocytes, haemoglobin, and total RBCs) was similar between these regimens. Additional studies compared the 40,000 IU once-weekly regimen of epoetin alfa with biweekly doses ranging from 80,000 to 120,000 IU subcutaneously. Overall, based on the results of</p><p>&nbsp;</p><p>these pharmacodynamic studies in healthy subjects, the 40,000 IU once-weekly dosing regimen seems to be more efficient in producing RBCs than the biweekly regimens despite an observed similarity in reticulocyte production in the once-weekly and biweekly regimens.</p><p>&nbsp;</p><p><em><u>Chronic renal failure</u></em></p><p>Epoetin alfa has been shown to stimulate erythropoiesis in anaemic patients with CRF, including dialysis and pre-dialysis patients. The first evidence of a response to epoetin alfa is an increase in the reticulocyte count within 10 days, followed by increases in the red cell count, haemoglobin and haematocrit, usually within 2 to 6 weeks. The haemoglobin response varies between patients and may be impacted by iron stores and the presence of concurrent medical problems.</p><p>&nbsp;</p><p><em><u>Chemotherapy-induced anaemia</u></em></p><p>Epoetin alfa administered 3 times per week or once weekly has been shown to increase haemoglobin and decrease transfusion requirements after the first month of therapy in anaemic cancer patients receiving chemotherapy.</p><p>&nbsp;</p><p>In a study comparing the 150 IU/kg, 3 times per week and 40,000 IU, once-weekly dosing regimens in healthy subjects and in anaemic cancer subjects the time profiles of changes in percent reticulocytes, haemoglobin, and total red blood cells were similar between the two dosing regimens in both healthy and anaemic cancer subjects. The AUCs of the respective pharmacodynamic parameters were similar between the 150 IU/kg, 3 times per week and 40,000 IU, once-weekly dosing regimens in healthy subjects and also in anaemic cancer subjects.</p><p>&nbsp;</p><p><em><u>Adult surgery patients in an autologous predonation programme</u></em></p><p>Epoetin alfa has been shown to stimulate red blood cell production in order to augment autologous blood collection, and to limit the decline in haemoglobin in adult patients scheduled for major elective surgery who are not expected to predeposit their complete perioperative blood needs. The greatest effects are observed in patients with low haemoglobin (&le; 13 g/dl).</p><p>&nbsp;</p><p><em><u>Treatment of adult patients scheduled for major elective orthopaedic surgery</u></em></p><p>In patients scheduled for major elective orthopaedic surgery with a pretreatment haemoglobin of &gt; 10 to &le; 13 g/dl, epoetin alfa has been shown to decrease the risk of receiving allogeneic transfusions and hasten erythroid recovery (increased haemoglobin levels, haematocrit levels, and reticulocyte counts).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>Chronic renal failure</u></em></p><p>Epoetin alfa has been studied in clinical trials in adult anaemic CRF patients, including haemodialysis and pre-dialysis patients, to treat anaemia and maintain haematocrit within a target concentration range of 30 to 36%.</p><p>&nbsp;</p><p>In clinical trials at starting doses of 50 to 150 IU/kg, three times per week, approximately 95% of all patients responded with a clinically significant increase in haematocrit. After approximately two months of therapy, virtually all patients were transfusion-independent. Once the target haematocrit was achieved, the maintenance dose was individualised for each patient.</p><p>&nbsp;</p><p>In the three largest clinical trials conducted in adult patients on dialysis, the median maintenance dose necessary to maintain the haematocrit between 30 to 36% was approximately 75 IU/kg given 3 times per week.</p><p>&nbsp;</p><p>In a double-blind, placebo-controlled, multicentre, quality of life study in CRF patients on haemodialysis, clinically and statistically significant improvement was shown in the patients treated with epoetin alfa compared to the placebo group when measuring fatigue, physical symptoms, relationships and depression (Kidney Disease Questionnaire) after six months of therapy. Patients from the group treated with epoetin alfa were also enrolled in an open-label extension study which demonstrated improvements in their quality of life that were maintained for an additional 12 months.</p><p>&nbsp;</p><p><em><u>Adult patients with renal insufficiency not yet undergoing dialysis</u></em></p><p>In clinical trials conducted in patients with CRF not on dialysis treated with epoetin alfa, the average duration of therapy was nearly five months. These patients responded to epoetin alfa therapy in a manner similar to that observed in patients on dialysis. Patients with CRF not on dialysis demonstrated a dose-dependent and sustained increase in haematocrit when epoetin alfa was administered by either an intravenous or subcutaneous route. Similar rates of rise of haematocrit were noted when epoetin alfa was administered by either route. Moreover, epoetin alfa doses of 75 to 150 IU/kg per week have been shown to maintain haematocrits of 36 to 38% for up to six months.</p><p>&nbsp;</p><p>In 2 studies with extended interval dosing of epoetin alfa (3 times per week, once weekly, once every 2 weeks, and once every 4 weeks) some patients with longer dosing intervals did not maintain adequate haemoglobin levels and reached protocol-defined haemoglobin withdrawal criteria (0% in once weekly, 3.7% in once-every-2-weeks, and 3.3% in the once-every-4-weeks groups).</p><p>&nbsp;</p><p>A randomised prospective trial evaluated 1,432 anaemic chronic renal failure patients who were not undergoing dialysis. Patients were assigned to epoetin alfa treatment targeting a maintenance haemoglobin level of 13.5 g/dl (higher than the recommended haemoglobin concentration level) or 11.3 g/dl. A major cardiovascular event (death, myocardial infarction, stroke or hospitalisation for congestive heart failure) occurred among 125 (18%) of the 715 patients in the higher haemoglobin group compared to 97 (14%) among the 717 patients in the lower haemoglobin group (hazard ratio [HR] 1.3, 95% CI: 1.0, 1.7, p = 0.03).</p><p>&nbsp;</p><p>Pooled post-hoc analyses of clinical studies of ESAs have been performed in chronic renal failure patients (on dialysis, not on dialysis, in diabetic and non-diabetic patients). A tendency towards increased risk estimates for all-cause mortality, cardiovascular and cerebrovascular events associated with higher cumulative ESA doses independent of the diabetes or dialysis status was observed (see section 4.2 and section 4.4).</p><p>&nbsp;</p><p><em><u>Treatment of patients with chemotherapy-induced anaemia</u></em></p><p>Epoetin alfa has been studied in clinical trials in adult anaemic cancer patients with lymphoid and solid tumors, and patients on various chemotherapy regimens, including platinum and non-platinum- containing regimens. In these trials, epoetin alfa administered 3 times per week and once weekly has been shown to increase haemoglobin and decrease transfusion requirements after the first month of therapy in anaemic cancer patients. In some studies, the double-blind phase was followed by an open- label phase during which all patients received epoetin alfa and a maintenance of effect was observed.</p><p>&nbsp;</p><p>Available evidence suggests patients with haematological malignancies and solid tumours respond equivalently to epoetin alfa therapy, and that patients with or without tumour infiltration of the bone marrow respond equivalently to epoetin alfa therapy. Comparable intensity of chemotherapy in the epoetin alfa and placebo groups in the chemotherapy trials was demonstrated by a similar area under the neutrophil time curve in patients treated with epoetin alfa and placebo-treated patients, as well as by a similar proportion of patients in groups treated with epoetin alfa and placebo-treated groups whose absolute neutrophil counts fell below 1,000 and 500 cells/&micro;l.</p><p>&nbsp;</p><p>In a prospective, randomised, double-blind, placebo-controlled trial conducted in 375 anaemic patients with various non-myeloid malignancies receiving non-platinum chemotherapy, there was a significant reduction of anaemia-related sequelae (e.g. fatigue, decreased energy, and activity reduction), as measured by the following instruments and scales: Functional Assessment of Cancer Therapy- Anaemia (FACT-An) general scale, FACT-An fatigue scale, and Cancer Linear Analogue Scale (CLAS). Two other smaller, randomised, placebo-controlled trials failed to show a significant improvement in quality of life parameters on the EORTC-QLQ-C30 scale or CLAS, respectively.</p><p>Survival and tumour progression have been examined in five large controlled studies involving a total of 2,833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study. The studies either recruited patients who were being treated with chemotherapy (two studies) or used patient populations in which ESAs are not indicated: anaemia in patients with cancer not receiving chemotherapy, and head and neck cancer patients receiving radiotherapy. The desired haemoglobin concentration level in two studies was &gt; 13 g/dl (8.1 mmol/l); in the remaining three studies it was 12 to 14 g/dl (7.5 to 8.7 mmol/l). In the open-label study there was no difference in</p><p>&nbsp;</p><p>overall survival between patients treated with recombinant human erythropoietin and controls. In the four placebo-controlled studies the hazard ratios for overall survival ranged between 1.25 and 2.47 in favour of controls. These studies have shown a consistent unexplained statistically significant excess mortality in patients who have anaemia associated with various common cancers who received recombinant human erythropoietin compared to controls. Overall survival outcome in the trials could not be satisfactorily explained by differences in the incidence of thrombosis and related complications between those given recombinant human erythropoietin and those in the control group.</p><p>&nbsp;</p><p>A patient-level data analysis has also been performed on more than 13,900 cancer patients (chemo-, radio-, chemoradio-, or no therapy) participating in 53 controlled clinical trials involving several epoetins. Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933 patients) and for the cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and 10,441 patients). Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see</p><p>section 4.4).</p><p>&nbsp;</p><p>A randomised, open-label, multicentre study was conducted in 2,098 anaemic women with metastatic breast cancer, who received first line or second line chemotherapy. This was a non inferiority study designed to rule out a 15% risk increase in tumour progression or death of epoetin alfa plus standard of care (SOC) as compared with SOC alone. At the time of clinical data cutoff, the median progression free survival (PFS) per investigator assessment of disease progression was 7.4 months in each arm (HR 1.09, 95% CI: 0.99, 1.20), indicating the study objective was not met. At clinical cutoff, 1337 deaths were reported. Median overall survival in the epoetin alfa plus SOC group was 17.2 months compared with 17.4 months in the SOC alone group (HR 1.06, 95% CI: 0.95, 1.18). Significantly fewer patients received RBC transfusions in the epoetin alfa plus SOC arm (5.8% versus 11.4%); however, significantly more patients had thrombotic vascular events in the epoetin alfa plus SOC arm (2.8% versus 1.4%). At the final analysis, 1653&nbsp;deaths were reported. Median overall survival in the epoetin alfa plus SOC group was&nbsp;17.8&nbsp;months compared with&nbsp;18.0&nbsp;months in the SOC alone group (HR&nbsp;1.07, 95% CI: 0.97, 1.18). The median time to progression (TTP) based on investigator-determined progressive disease (PD) was 7.5 months in the epoetin alfa plus SOC group and 7.5 months in the SOC group (HR 1.099, 95% CI: 0.998, 1.210). The median TTP based on IRC-determined PD was 8.0 months in the epoetin alfa plus SOC group and 8.3 months in the SOC group (HR 1.033, 95% CI: 0.924, 1.156).</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Autologous predonation programme</u></em></p><p>The effect of epoetin alfa in facilitating autologous blood donation in patients with low haematocrits (&le; 39% and no underlying anaemia due to iron deficiency) scheduled for major orthopaedic surgery was evaluated in a double-blind, placebo-controlled study conducted in 204 patients, and a single- blind placebo controlled study in 55 patients.</p><p>&nbsp;</p><p>In the double-blind study, patients were treated with epoetin alfa 600 IU/kg or placebo intravenously once daily every 3 to 4 days over 3 weeks (total 6 doses). On average, patients treated with epoetin alfa were able to predeposit significantly more units of blood (4.5 units) than placebo-treated patients (3.0 units).</p><p>&nbsp;</p><p>In the single-blind study, patients were treated with epoetin alfa 300 IU/kg or 600 IU/kg or placebo intravenously once daily every 3 to 4 days over 3 weeks (total 6 doses). Patients treated with epoetin alfa were also able to predeposit significantly more units of blood (epoetin alfa 300 IU/kg = 4.4 units; epoetin alfa 600 IU/kg = 4.7 units) than placebo-treated patients (2.9 units).</p><p>&nbsp;</p><p>Epoetin alfa therapy reduced the risk of exposure to allogeneic blood by 50% compared to patients not receiving epoetin alfa.</p><p>&nbsp;</p><p><em><u>Major elective orthopaedic surgery</u></em></p><p>The effect of epoetin alfa (300 IU/kg or 100 IU/kg) on the exposure to allogeneic blood transfusion has been evaluated in a placebo-controlled, double-blind clinical trial in non-iron deficient adult patients scheduled for major elective orthopaedic hip or knee surgery. Epoetin alfa was administered subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.</p><p>&nbsp;Patients were stratified according to their baseline haemoglobin (&le;&nbsp;10&nbsp;g/dL, &gt;&nbsp;10&nbsp;to &le;&nbsp;13&nbsp;g/dL and &gt;&nbsp;13&nbsp;g/dL).</p><p>&nbsp;</p><p>Epoetin alfa 300 IU/kg significantly reduced the risk of allogeneic transfusion in patients with a pretreatment haemoglobin of &gt; 10 to &le; 13 g/dl. Sixteen percent of epoetin alfa 300 IU/kg, 23% of epoetin alfa 100 IU/kg and 45% of placebo-treated patients required transfusion.</p><p>&nbsp;</p><p>An open-label, parallel-group trial in non-iron deficient adult subjects with a pretreatment haemoglobin of &ge; 10 to &le; 13 g/dl who were scheduled for major orthopaedic hip or knee surgery compared epoetin alfa 300 IU/kg subcutaneously daily for 10 days prior to surgery, on the day of surgery and for four days after surgery to epoetin alfa 600 IU/kg subcutaneously once weekly for 3 weeks prior to surgery and on the day of surgery.</p><p>&nbsp;</p><p>From pretreatment to presurgery, the mean increase in haemoglobin in the 600 IU/kg weekly group (1.44 g/dl) was twice than that observed in the 300 IU/kg daily group (0.73 g/dl). Mean haemoglobin levels were similar for the two treatment groups throughout the postsurgical period.</p><p>&nbsp;</p><p>The erythropoietic response observed in both treatment groups resulted in similar transfusion rates (16% in the 600 IU/kg weekly group and 20% in the 300 IU/kg daily group).</p><p>&nbsp;</p><p><em><u>Treatment of adult patients with low- or intermediate-1-risk MDS</u></em></p><p>A randomised, double-blind, placebo-controlled, multicentre study evaluated the efficacy and safety of epoetin alfa in adult anaemic subjects with low- or intermediate-1-risk MDS.</p><p>&nbsp;</p><p>Subjects were stratified by serum erythropoetin (sEPO) level and prior transfusion status at screening. Key baseline characteristics for the &lt; 200 mU/mL stratum are shown in the table below.</p><p>&nbsp;</p><p><u>&nbsp;&nbsp;Baseline Characteristics for Subjects with sEPO &lt; 200 mU/mL at Screening&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Total (N)b</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Epoetin alfa</p></td><td style="vertical-align:top"><p>Randomised</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Placebo</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>85a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>45</p></td></tr><tr><td style="vertical-align:top"><p>Screening sEPO &lt; 200 mU/mL (N)</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>39</p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin (g/l)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>39</p></td></tr><tr><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top"><p>92.1 (8.57)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>92.1 (8.51)</p></td></tr><tr><td style="vertical-align:top"><p>Median</p></td><td style="vertical-align:top"><p>94.0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>96.0</p></td></tr><tr><td style="vertical-align:top"><p>Range</p></td><td style="vertical-align:top"><p>(71, 109)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(69, 105)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI for mean</p></td><td style="vertical-align:top"><p>(90.1, 94.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(89.3, 94.9)</p></td></tr><tr><td style="vertical-align:top"><p>Prior Transfusions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>39</p></td></tr><tr><td style="vertical-align:top"><p>Yes</p></td><td style="vertical-align:top"><p>31 (43.7%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>17 (43.6%)</p></td></tr><tr><td style="vertical-align:top"><p>&le; 2 RBC Units</p></td><td style="vertical-align:top"><p>16 (51.6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>9 (52.9%)</p></td></tr><tr><td style="vertical-align:top"><p>&gt;2 and &le;4 RBC Units</p></td><td style="vertical-align:top"><p>14 (45.2%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>8 (47.1%)</p></td></tr><tr><td style="vertical-align:top"><p>&gt;4 RBC Units</p></td><td style="vertical-align:top"><p>1 (3.2%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>No</p></td><td style="vertical-align:top"><p>40 (56.3%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>22 (56.4%)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_2" o:spid="_x0000_s1026" style='position:absolute;
  margin-left:65.25pt;margin-top:12.4pt;width:464.8pt;height:.5pt;z-index:251667456;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordorigin="1305,248" coordsize="9296,10"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:line id="Line_x0020_28" o:spid="_x0000_s1027" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="1310,253" to="5246,253"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <v:line id="Line_x0020_29" o:spid="_x0000_s1028" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="5246,253" to="5256,253"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <v:line id="Line_x0020_30" o:spid="_x0000_s1029" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="5256,253" to="7939,253"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".48pt"/>
  <v:line id="Line_x0020_31" o:spid="_x0000_s1030" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="7939,253" to="7949,253"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAHe0RHwgAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9PawIx
FMTvgt8hPKE3zdaDymqUVvAP7ElbaI+P5LlZunlZNunu+u2bguBxmJnfMJvd4GrRURsqzwpeZxkI
Yu1NxaWCz4/DdAUiRGSDtWdScKcAu+14tMHc+J4v1F1jKRKEQ44KbIxNLmXQlhyGmW+Ik3fzrcOY
ZFtK02Kf4K6W8yxbSIcVpwWLDe0t6Z/rr1PQnYrvrlh61Kev4t3qw7Fa9kelXibD2xpEpCE+w4/2
2ShYwP+VdAPk9g8AAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQAHe0RHwgAAANoAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" strokeweight=".48pt"/>
  <v:line id="Line_x0020_32" o:spid="_x0000_s1031" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="7949,253" to="10596,253"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".48pt"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="621" height="1" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.png" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>a one subject did not have sEPO data</p><p>b in the &ge; 200 mU/mL stratum there were 13 subjects in the epoetin alfa group and 6 subjects in the placebo group</p><p>&nbsp;</p><p>Erythroid response was defined according to International Working Group (IWG) 2006 criteria as a haemoglobin increase &ge; 1.5 g/dl from baseline or a reduction of RBC units transfused by an absolute number of at least 4 units every 8 weeks compared to the 8 weeks prior to baseline, and a response duration of at least 8 weeks.</p><p>&nbsp;</p><p>Erythroid response during the first 24 weeks of the study was demonstrated by 27/85 (31.8%) of the subjects in the epoetin alfa group compared to 2/45 (4.4%) of the subjects in the placebo group</p><p>(p &lt; 0.001). All of the responding subjects were in the stratum with sEPO &lt; 200 mU/mL during screening. In that stratum, 20/40 (50%) subjects without prior transfusions demonstrated erythroid response during the first 24 weeks, compared with 7/31 (22.6%) subjects with prior transfusions (two subjects with prior transfusion reached primary endpoint based on reduction of RBC units transfused by an absolute number of at least 4 units every 8 weeks compared to the 8 weeks prior to baseline).</p><p>&nbsp;</p><p>Median time from baseline to first transfusion was statistically significantly longer in the epoetin alfa group compared to placebo (49 vs. 37 days; p = 0.046). After 4 weeks of treatment the time to first transfusion was further increased in the epoetin alfa group (142 vs. 50 days, p = 0.007). The percentage of subjects who were transfused in the epoetin alfa group decreased from 51.8% in the</p><p>8&nbsp;weeks prior to baseline to&nbsp;24.7% between weeks&nbsp;16&nbsp;and&nbsp;24, compared to the placebo group which had an increase in transfusion rate from&nbsp;48.9% to&nbsp;54.1% over the same time periods.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p><em><u>Chronic renal failure</u></em></p><p>Epoetin alfa was evaluated in an open-label, non-randomised, open dose-range, 52-week clinical study in paediatric CRF patients undergoing haemodialysis. The median age of patients enrolled in the study was 11.6 years (range 0.5 to 20.1 years).</p><p>&nbsp;</p><p>Epoetin alfa was administered at 75 IU/kg/week intravenously in 2 or 3 divided doses post-dialysis, titrated by 75 IU/kg/week at intervals of 4 weeks (up to a maximum of 300 IU/kg/week), to achieve a 1 g/dl/month increase in haemoglobin. The desired haemoglobin concentration range was 9.6 to 11.2 g/dl. Eighty-one percent of patients achieved the haemoglobin concentration level. The median time to target was 11 weeks and the median dose at target was 150 IU/kg/week. Of the patients who achieved the target, 90% did so on a 3 times-per-week dosing regimen.</p><p>&nbsp;</p><p>After 52 weeks, 57% of patients remained in the study, receiving a median dose of 200 IU/kg/week.</p><p>&nbsp;</p><p>Clinical data with subcutaneous administration in children are limited. In 5 small, open label, uncontrolled studies (number of patients ranged from 9-22, total N = 72), Epoetin alfa has been administered subcutaneously in children at starting doses of 100 IU/kg/week to 150 IU/kg/week with the possibility to increase up to 300 IU/kg/week. In these studies, most were predialysis patients</p><p>(N = 44), 27 patients were on peritoneal dialysis and 2 were on haemodialysis with age ranging from 4 months to 17 years. Overall, these studies have methodological limitations but treatment was associated with positive trends towards higher haemoglobin levels. No unexpected adverse events were reported (see section 4.2).</p><p>&nbsp;</p><p><em><u>Chemotherapy-induced anaemia</u></em></p><p><em>&nbsp;</em></p><p>Epoetin alfa 600 IU/kg (administered intravenously or subcutaneously once weekly) has been evaluated in a randomised, double-blind, placebo-controlled, 16-week study and in a randomised, controlled, open-label, 20-week study in anaemic paediatric patients receiving myelosuppressive chemotherapy for the treatment of various childhood non-myeloid malignancies.</p><p>&nbsp;</p><p>In the 16-week study (n = 222), in the epoetin alfa-treated patients there was no statistically significant effect on patient-reported or parent-reported Paediatric Quality of Life Inventory or Cancer Module scores compared with placebo (primary efficacy endpoint). In addition, there was no statistical difference between the proportion of patients requiring pRBC transfusions between the Epoetin alfa group and placebo.</p><p>&nbsp;</p><p>In the 20-week study (n = 225), no significant difference was observed in the primary efficacy endpoint, i.e. the proportion of patients who required a RBC transfusion after Day 28 (62% of epoetin alfa patients versus 69% of standard therapy patients).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Absorption</u></em></p><p>Following subcutaneous injection, serum levels of epoetin alfa reach a peak between 12 and 18 hours post-dose. There was no accumulation after multiple dose administration of 600 IU/kg administered subcutaneously weekly.</p><p>&nbsp;</p><p>The absolute bioavailability of subcutaneous injectable epoetin alfa is approximately 20% in healthy subjects.</p><p>&nbsp;</p><p><em><u>Distribution</u></em></p><p>The mean volume of distribution was 49.3 mL/kg after intravenous doses of 50 and 100 IU/kg in healthy subjects. Following intravenous administration of epoetin alfa in subjects with chronic renal failure, the volume of distribution ranged from 57-107 mL/kg after single dosing (12 IU/kg) to 42&ndash; 64 mL/kg after multiple dosing (48&ndash;192 IU/kg), respectively. Thus, the volume of distribution is slightly greater than the plasma space.</p><p><em><u>Elimination</u></em></p><p>The half-life of epoetin alfa following multiple dose intravenous administration is approximately 4 hours in healthy subjects.</p><p>The half-life for the subcutaneous route is estimated to be approximately 24 hours in healthy subjects.</p><p>The mean CL/F for the 150 IU/kg 3 times-per-week and 40,000 IU once-weekly regimens in healthy subjects were 31.2 and 12.6 mL/h/kg, respectively. The mean CL/F for the 150 IU/kg,</p><p>3 times-per-week and 40,000 IU, once-weekly regimens in the anaemic cancer subjects were 45.8 and</p><p>11.3 mL/h/kg, respectively. In most anaemic subjects with cancer receiving cyclic chemotherapy, CL/F was lower after subcutaneous doses of 40,000 IU once weekly and 150 IU/kg, 3 times-per-week compared with the values for healthy subjects.</p><p>&nbsp;</p><p><em><u>Linearity/Non-linearity</u></em></p><p>In healthy subjects, a dose-proportional increase in serum epoetin alfa concentrations was observed after intravenous administration of 150 and 300 IU/kg, 3 times per week. Administration of single doses of 300 to 2,400 IU/kg subcutaneous epoetin alfa resulted in a linear relationship between mean Cmax and dose and between mean AUC and dose. An inverse relationship between apparent clearance and dose was noted in healthy subjects.</p><p>&nbsp;</p><p>In studies to explore extending the dosing interval (40,000 IU once weekly and 80,000, 100,000, and 120,000 IU biweekly), a linear but non-dose-proportional relationship was observed between mean Cmax and dose, and between mean AUC and dose at steady state.</p><p>&nbsp;</p><p>Pharmacokinetic/pharmacodynamic relationships</p><p>Epoetin alfa exhibits a dose-related effect on haematological parameters which is independent of route of administration.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>A half-life of approximately 6.2 to 8.7 hours has been reported in paediatric subjects with chronic renal failure following multiple dose intravenous administration of epoetin alfa. The pharmacokinetic profile of epoetin alfa in children and adolescents appears to be similar to that of adults.</p><p>&nbsp;</p><p>Pharmacokinetic data in neonates is limited.</p><p>&nbsp;</p><p>A study of 7 preterm very low birth weight neonates and 10 healthy adults given i.v. erythropoietin suggested that distribution volume was approximately 1.5 to 2 times higher in the preterm neonates than in the healthy adults, and clearance was approximately 3 times higher in the preterm neonates than in healthy adults.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>In chronic renal failure patients, the half-life of intravenously administered epoetin alfa is slightly prolonged, approximately 5 hours, compared to healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeated dose toxicological studies in dogs and rats, but not in monkeys, epoetin alfa therapy was associated with subclinical bone marrow fibrosis. Bone marrow fibrosis is a known complication of chronic renal failure in humans and may be related to secondary hyperparathyroidism or unknown factors. The incidence of bone marrow fibrosis was not increased in a study of haemodialysis patients who were treated with epoetin alfa for 3 years compared to a matched control group of dialysis patients who had not been treated with epoetin alfa.</p><p>&nbsp;</p><p>Epoetin alfa does not induce bacterial gene mutation (Ames Test), chromosomal aberrations in mammalian cells, micronuclei in mice, or gene mutation at the HGPRT locus.</p><p>Long-term carcinogenicity studies have not been carried out. Conflicting reports in the literature, based on <em>in vitro </em>findings from human tumour samples, suggest erythropoietins may play a role as tumour proliferators. This is of uncertain significance in the clinical situation.</p><p>&nbsp;</p><p>In cell cultures of human bone marrow cells, epoetin alfa stimulates erythropoiesis specifically and does not affect leucopoiesis. Cytotoxic actions of epoetin alfa on bone marrow cells could not be detected.</p><p>In animal studies, epoetin alfa has been shown to decrease foetal body weight, delay ossification and increase foetal mortality when given in weekly doses of approximately 20 times the recommended human weekly dose. These changes are interpreted as being secondary to decreased maternal body weight gain, and the significance to humans is unknown given therapeutic dose levels.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium dihydrogen phosphate dihydrate</p><p>Disodium phosphate dihydrate</p><p>Sodium chloride</p><p>Glycine</p><p>Polysorbate 80</p><p>Water for injections</p><p>Hydrochloric acid (for pH adjustment)</p><p>Sodium hydroxide (for pHadjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport refrigerated (2&deg;C to 8&deg;C). This temperature range should be closely maintained until administration to the patient.</p><p>For the purpose of ambulatory use, the medicinal product may be taken out of the refrigerator, without being replaced, for a maximum period of 3 days at a temperature not above 25&deg;C. If the medicinal product has not been used at the end of this period, it should be disposed of.</p><p>&nbsp;</p><p>Do not freeze or shake.</p><p>Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pre-filled syringes (glass type I), with or without a needle safety guard, with plunger stopper (Teflon- faced rubber) sealed in a blister.</p><p>&nbsp;</p><p><u>Binocrit 1,000 IU/0.5 mL solution for injection in a pre-filled syringe </u>Each syringe contains 0.5 mL of solution for injection.</p><p>Pack of 1 or 6 syringes.</p><p>&nbsp;</p><p><u>Binocrit 2,000 IU/1 mL solution for injection in a pre-filled syringe </u>Each syringe contains 1 mL of solution for injection.</p><p>Pack of 1 or 6 syringes.</p><p><u>Binocrit 4,000 IU/0.4 mL solution for injection in a pre-filled syringe </u>Each syringe contains 0.4 mL of solution for injection.</p><p>Pack of 1 or 6 syringes.</p><p>&nbsp;</p><p><u>Binocrit 10,000 IU/1 mL solution for injection in a pre-filled syringe </u>Each syringe contains 1 mL of solution for injection.</p><p>Pack of 1 or 6 syringes.</p><p>&nbsp;</p><p><u>Binocrit 20,000 IU/0.5 mL solution for injection in a pre-filled syringe </u>Each syringe contains 0.5 mL of solution for injection.</p><p>Pack of 1, 4 or 6 syringes.</p><p>&nbsp;</p><p><u>Binocrit 30,000 IU/0.75 mL solution for injection in a pre-filled syringe </u>Each syringe contains 0.75 mL of solution for injection.</p><p>Pack of 1, 4 or 6 syringes.</p><p>&nbsp;</p><p><u>Binocrit 40,000 IU/1 mL solution for injection in a pre-filled syringe </u>Each syringe contains 1 mL of solution for injection.</p><p>Pack of 1, 4 or 6 syringes.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Binocrit should not be used and discarded</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the liquid is coloured or you can see particles floating in it,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the seal is broken,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you know, or think that it may have been accidentally frozen, or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if there has been a refrigerator failure.</p><p>&nbsp;</p><p>The pre-filled syringes are ready to use (see section 4.2). The pre-filled syringe should not be shaken. Syringes are embossed with graduation rings in order to enable partial use if required. Each graduation ring corresponds to a volume of 0.1 mL. The product is for single use only. Only take one dose of Binocrit from each syringe discarding unwanted solution before injection.</p><p><u>Using the pre-filled syringe with a needle safety guard</u></p><p>&nbsp;</p><p>The needle safety guard covers the needle after injection to prevent needle stick injury. This does not affect normal operation of the syringe. Depress the plunger slowly and evenly until the entire dose has been given and the plunger cannot be depressed any further. While maintaining pressure on the plunger, remove the syringe from the patient. The needle safety guard will cover the needle when releasing the plunger.</p><p>&nbsp;</p><p><u>Using the pre-filled syringe without a needle safety guard </u>Administer the dose as per standard protocol.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandoz GbmH Biochemiestr. 10 A-6250 Kundl Austria


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>